ClinicalTrials.gg
CompletedNCT03596762SWITCH-1Updated Mar 10, 2023Results posted

A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms

A Phase 2 interventional study of Elinzanetant (BAY3427080) and Placebo in Menopause, Hot Flashes and Night Waking, sponsored by Bayer. Completed at 25 sites in 3 countries. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-03-10.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
199
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing elinzanetant in Hot Flashes — none open to participants now, 1 under way, 1 of them phase 3. elinzanetant · Hot Flashes.

Enrollment
5th of 13
199 · median 64
Started
2018
the only one that year
Phase 2
Only one
of the 13
Registered
2nd of 13
by date
Lead sponsor
13 of 13
Bayer

Among the 13 studies testing elinzanetant in Hot Flashes, this one is the 5th largest by enrollment, is the only one that started in 2018, is the only one in phase 2, and was the 2nd registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 13 studies testing elinzanetant in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

About elinzanetant

elinzanetant: first FDA approval 2025 (LYNKUET), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing elinzanetant in Hot Flashes as a file.
02

Study summary

The purpose of this study is to determine the effectiveness of BAY3427080 (NT-814), taken once a day, in the treatment of troublesome post-menopausal symptoms.

Read the detailed description

This is a multi-centre, multi-country, double-blind, randomised, placebo-controlled Phase 2b study. The study will have a single-blind run-in period and will be adaptive with respect to the number of subjects recruited into each dose group. Four doses of BAY3427080 (40 mg once a day, 80 mg once a day, 120 mg once a day and 160 mg once a day) will be investigated and compared to placebo, in five parallel groups. Subjects will participate in the study for a total of approximately 19 weeks, comprising a screening period of 1 week, a 14 week treatment period, and then a final follow up visit 4 weeks after the end of the treatment period. There will be a total of 8 visits whilst participating in the study. Subjects will record their hot flashes in an electronic diary during the screening period to establish eligibility and throughout the study after randomisation.

03

Conditions studied

  • Menopause
  • Hot Flashes
  • Night Waking

Browse trials for

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • between 18 and 38 kg/m2, inclusive
  • Subject experiences moderate or severe hot flashes

Key Exclusion Criteria:

  • Inability to comply with the use of prohibited and allowed medications as described in the protocol.
  • Any prior or ongoing history of drug or alcohol abuse within 12 months of Screening.
  • Any clinically significant prior or ongoing history of arrhythmias, either determined through clinical history or on evaluation.
  • Any clinically significant abnormal laboratory test result(s) measured at Screening.
  • Any active ongoing condition that could have caused difficulty in interpreting vasomotor symptoms.
  • Uncontrolled hypertension.
  • A history or hyperthyroidism, hypothyroidism or abnormal thyroid function tests at Screening. Treated hypothyroidism with normal thyroid function test results at Screening is acceptable.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
199 participants (actual)

Study arms

  • Experimental
    160 mg Elinzanetant (BAY3427080)

    Participants received 4x40 mg elinzanetant capsules.

    Drug: Elinzanetant (BAY3427080)

  • Experimental
    120 mg Elinzanetant (BAY3427080)

    Participants received 3x40 mg elinzanetant capsules and 1 placebo capsule.

    Drug: Elinzanetant (BAY3427080)

  • Experimental
    80 mg Elinzanetant (BAY3427080)

    Participants received 2x40 mg elinzanetant capsules and 2 placebo capsules.

    Drug: Elinzanetant (BAY3427080)

  • Experimental
    40 mg Elinzanetant (BAY3427080)

    Participants received one 40 mg elinzanetant capsule and 3 placebo capsules.

    Drug: Elinzanetant (BAY3427080)

  • Placebo comparator
    Placebo

    Participants received four placebo capsules orally once daily in the evening before bedtime.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 4

    Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.

    Time frame: From baseline to Week 4

  2. Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 12

    Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.

    Time frame: From baseline to Week 12

  3. Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 4

    Participants recorded daily in their eDiary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).

    Time frame: From baseline to Week 4

  4. Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 12

    Participants recorded daily in their eDiary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity was graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).

    Time frame: From baseline to Week 12

Secondary outcomes

  1. Mean Change From Baseline in Frequency of Mean Daily Moderate and Severe Hot Flushes From Baseline to Weeks 1, 2, 8 and 16

    Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.

    Time frame: From baseline to Weeks 1, 2, 8 and 16

  2. Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Weeks 1, 2, 8 and 16

    Participants recorded daily in their diary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).

    Time frame: From baseline to Weeks 1, 2, 8 and 16

  3. Mean Change From Baseline in Mean Daily Frequency of All Hot Flushes From Baseline to Weeks 1, 2, 4, 8, 12 and 16

    Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.

    Time frame: From baseline to Weeks 1, 2, 4, 8, 12 and 16

  4. Mean Change From Baseline in Mean Severity of All Hot Flushes From Baseline to Weeks 1, 2, 4, 8, 12 and 16

    Participants recorded daily in their diary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).

    Time frame: From baseline to Weeks 1, 2, 4, 8, 12 and 16

  5. Mean Change From Baseline in the Mean Daily Hot Flush Score (Frequency x Severity) at Weeks 1, 2, 4, 8, 12 and 16

    Mean daily Hot Flushes score = Sum of (frequency x severity) filled in the diary during the last 7 days (with at least one available data in the evening and/or morning) divided by 7. Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).

    Time frame: From baseline to Weeks 1, 2, 4, 8, 12 and 16

  6. Number of Participants With ≥50% and ≥80% Reduction From Baseline in Mean Daily Hot Flushes Frequency at Week 12

    The percent change from baseline at a visit Week 12 was calculated. Percent change = (change from baseline in mean daily frequency of moderate and severe hot flushes from baseline to Week 12 / Mean daily frequency of moderate and severe hot flushes at baseline) \* 100. A participant was considered as a responder with a reduction of ≥50% (or ≥80%) if the percent change was ≤-50 (or ≤-80).

    Time frame: Week 12

  7. Mean Change From Baseline in Number of All Night-time Awakenings (NTA) at Weeks 1, 2, 4, 8, 12 and 16

    Participants were provided with an eDiary to document the number of night-time awakenings (NTA). Each evening, participants recorded the total number of hot flushes of each severity experienced that day since waking. Each morning upon waking, subjects recorded the number of times they woke up in the night and the total number of hot flushes of each severity experienced during the night.

    Time frame: From baseline to Weeks 1, 2, 4, 8, 12 and 16

  8. Mean Change From Baseline in Mean Daily Number of NTAs Secondary to Hot Flushes at Weeks 1, 2, 4, 8, 12 and 16

    Subjects were provided with an eDiary to document the number of night-time awakenings (NTA). Each evening, subjects recorded the total number of hot flashes of each severity experienced that day since waking. Each morning upon waking, subjects recorded the number of times they woke up in the night and the total number of hot flushes of each severity experienced during the night. Night-time awakenings secondary to hot flashes corresponded to severe hot flash recorded on the morning diary, and all NTAs corresponded to the data recorded in the "Total number of times you woke up last night?" field from the eDiary recorded in the morning. Number of NTAs secondary to hot flushes could not be higher than the number of all NTAs.

    Time frame: From baseline to Weeks 1, 2, 4, 8, 12 and 16

  9. Change From Baseline in the Global and Individual Domain Scores of the Pittsburgh Sleep Quality Index (PSQI) at Weeks 4, 8, 12 and 16

    The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. The PSQI uses 19 individual items to generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction, each scored 0 (no difficulty) to 3 (severe difficulty). The sum of scores for these seven components yields one global score (range 0 to 21). Higher scores indicated worse sleep quality.

    Time frame: From baseline to Weeks 4, 8, 12 and 16

  10. Change From Baseline in the Insomnia Severity Index (ISI) Score at Weeks 4, 8, 12 and 16

    The ISI is a brief self-report questionnaire assessing the nature, severity, and impact of insomnia. The ISI comprises seven items assessing the perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Participants rated each item on a scale of 0 to 4, yielding a total score ranging from 0 to 28. The total score was calculated by adding the scores for all seven items. Higher scores indicated severe insomnia.

    Time frame: From baseline to Weeks 4, 8, 12 and 16

  11. Change From Baseline in the Hot Flush Related Daily Interference Scale (HFRDIS) Scores at Weeks 2, 4, 8, 12 and 16

    The HFRDIS is a 10-item, self-report questionnaire assessing the impact of hot flushes on a woman's life during the past week. For each of the 10 items, participants rated how much hot flushes had interfered with that aspect of their life on a scale of 0 (not at all) to 10 (very much so). The total score was calculated by adding the scores for all 10 items. Higher scores indicated greater interference.

    Time frame: From baseline to Weeks 2, 4, 8, 12 and 16

  12. Change From Baseline in the Menopause-specific Quality-of-Life Questionnaire Intervention Version (MenQoL-I) Scores at Weeks 4, 8, 12 and 16

    The MenQoL-I is a validated questionnaire used to measure condition-specific quality of life in menopausal women. It is composed of 32 items across four domains (physical, vasomotor, psychosocial and sexual). For each item, participants recorded whether they had experienced the problem in the past month, and if so, they rated how bothered they were by the problem on a scale of 0 (not at all bothered) to 6 (extremely bothered). The item scores were converted to a score ranging from 1 to 8. Domain scores are calculated by averaging the converted individual item scores (range 1-8) related to the respective domain. (Domains: Vasomotor - items 1 to 3, Psychosocial - items 4 to 10, Physical- items 11- to 26, Sexual - items 27 to 29). For a MENQOL total score the aggregated mean of the mean domain scores is calculated. Higher scores indicate greater bother.

    Time frame: From baseline to Weeks 4, 8, 12 and 16;

  13. Change From Baseline in the Beck Depression Inventory II (BDI-II) Scores at Weeks 2, 4, 8, 12 and 16

    The BDI-II is a 21-item questionnaire assessing the intensity of depressive symptoms over the past 2 weeks. It is composed of items relating to symptoms of depression such as hopelessness and irritability, cognitions such as guilt or feelings of being punished, as well as physical symptoms such as fatigue, weight loss, and lack of interest in sex. Participants rated each item on a scale of 0 to 3 to give a total score ranging from 0 to 63, with a higher score suggesting more severe depressive symptoms.

    Time frame: From baseline to Weeks 2, 4, 8, 12 and 16

  14. Plasma Elinzanetant Concentrations at Weeks 2, 4, 8 ,12

    Blood samples for analysis of plasma elinzanetant concentrations were collected at Weeks 2, 4, 8, and 12. A small number of participants had elinzanetant concentrations below the LOQ for the assay (1.5 ng/mL) at two or more visits (three participants in each of the 40 mg, 120 mg, and 160 mg groups, four in 80 mg group), indicating that these subjects were non compliant with treatment.

    Time frame: At Weeks 2, 4, 8 ,12

  15. Nature and Severity of Adverse Events

    A Treatment-Emergent Adverse Events (TEAE) is defined as any adverse event (serious and non-serious) with the onset date on or after the date of first dosing with study treatment. Safety Analysis Set.

    Time frame: Up to Week 16

  16. Withdrawals Due to an Adverse Event

    A Treatment-Emergent Adverse Events (TEAE) is defined as any adverse event (serious and non-serious) with the onset date on or after the date of first dosing with study treatment.

    Time frame: Up to Week 16

  17. Number of Subjects Used Concomitant Medications

    A concomitant medication is defined as any medication used on or after date and time of first randomised treatment. All concomitant medications taken during the study were recorded in the eCRF. Any medication that was not specifically prohibited was allowed. (1) Antidiarrheals, intestinal antiinflammatory/antiinfective agents.

    Time frame: Up to Week 16

  18. Change From Baseline in Vital Signs (Systolic Blood Pressure) at Weeks 2, 4, 8, 12 and 16

    Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.

    Time frame: From baseline to Weeks 2, 4, 8, 12 and 16

  19. Change From Baseline in Vital Signs (Diastolic Blood Pressure) at Weeks 2, 4, 8, 12 and 16

    Vital signs, including systolic and diastolic blood pressure were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.

    Time frame: From baseline to Weeks 2, 4, 8, 12 and 16

  20. Change From Baseline in Vital Signs (Pulse Rate) at Weeks 2, 4, 8, 12 and 16

    Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.

    Time frame: From baseline to Weeks 2, 4, 8, 12 and 16

  21. Change From Baseline in Vital Signs (Temperature) at Weeks 2, 4, 8, 12 and 16

    Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.

    Time frame: From baseline to Weeks 2, 4, 8, 12 and 16

  22. Change From Baseline in Vital Signs (Weight) at Weeks 2, 4, 8, 12 and 16

    Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.

    Time frame: From baseline to Weeks 2, 4, 8, 12 and 16

  23. Change From Baseline in Vital Signs (Body Mass Index ) at Weeks 2, 4, 8, 12 and 16

    Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.

    Time frame: From baseline to Weeks 2, 4, 8, 12 and 16

  24. Change From Baseline in Vital Signs (Waist Circumference) at Weeks 2, 4, 8, 12 and 16

    Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.

    Time frame: From baseline to Weeks 2, 4, 8, 12 and 16

  25. Number of Subjects With Normal Electrocardiogram (ECG) Findings at Each Visit

    All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reported results are cardiovascular system-examination findings. Normal ECG was decided by investigator. The findings are presented as Normal ECG.

    Time frame: At Weeks 2, 4, 8, 12 and 16

  26. Number of Subjects With Abnormal Not Clinically Significant ECG Findings at Each Visit

    All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reported results are cardiovascular system-examination findings. Abnormal not clinically significant ECG findings were decided by investigator. The findings are presented as Abnormal not clinically significant ECG.

    Time frame: At Weeks 2, 4, 8, 12 and 16

  27. Number of Subjects With Abnormal Clinically Significant ECG Findings at Each Visit

    All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reported results are cardiovascular system-examination findings. Abnormal clinically significant ECG findings were decided by investigator. The findings are presented as Abnormal clinically significant ECG.

    Time frame: At Weeks 2, 4, 8, 12 and 16

  28. Change From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (RR)

    All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record. In categories the number of subjects analyzed (N) for each week is mentioned for each reporting group respectively.

    Time frame: At Weeks 2, 4, 8, 12 and 16

  29. Change From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (PR)

    All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record.

    Time frame: At Weeks 2, 4, 8, 12 and 16

  30. Change From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (QT)

    All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record.

    Time frame: At Weeks 2, 4, 8, 12 and 16

  31. Change From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (QTc)

    All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record. QTc: QT corrected interval.

    Time frame: At Weeks 2, 4, 8, 12 and 16

  32. Change From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (QTcF)

    All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record. QTcF: QT interval with Fridericia's correction.

    Time frame: At Weeks 2, 4, 8, 12 and 16

  33. Number of Subjects With Absolute QTcF Values by Category at Each Visit: ≤450, >450 to ≤480, >480 to ≤500, >500 Msec

    Absolute QTcF values reported.

    Time frame: From baseline to Weeks 2, 4, 8, 12 and 16

  34. Number of Subjects With Change From Baseline in ECG QTcF Values by Category at Weeks 2, 4, 8, 12 and 16: ≤0, >0 to ≤30, >30 to ≤60, >60 Msec

    Increase from Baseline overtime was reported.

    Time frame: From baseline to Weeks 2, 4, 8, 12 and 16

  35. Change From Baseline in the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS) at Weeks 4, 12 and 16

    The Columbia Suicide Severity Rating Scale (C-SSRS) is a rating scale created to evaluate suicidality in adults and children over the age of 12. It rates an individual's degree of suicidal ideation on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The version used was the eC-SSRS, which is a subject-reported version of the scale. Shifts from baseline versus post-baseline to demonstrate changes in categories (cat) were reported using cat 1 (No Suicidal Ideation or Behaviour), cat 2 (Suicidal Ideation) and cat 3 (Suicidal Behaviour).

    Time frame: Baseline to Weeks 4, 12 and 16

  36. Change From Baseline at Weeks 2, 4, 12 and 16 for Clinical Laboratory Parameters Hematology: Erythrocytes

    Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.

    Time frame: From baseline to Weeks 2, 4, 12 and 16

  37. Change From Baseline at Weeks 2, 4, 12 and 16 for Clinical Laboratory Parameters Hematology: Hematocrit

    Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.

    Time frame: From baseline to Weeks 2, 4, 12 and 16

  38. Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Hematology: Hemoglobin

    Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.

    Time frame: From baseline to Weeks 2, 4, 12 and 16

  39. Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Hematology: Erythrocytes Mean Corpuscular Volume

    Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.

    Time frame: From baseline to Weeks 2, 4, 12 and 16

  40. Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Hematology: Leukocytes, Platelets, Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils

    Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.

    Time frame: From baseline to Weeks 2, 4, 12 and 16

  41. Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Hematology: Leukocytes, Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils

    Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.

    Time frame: From baseline to Weeks 2, 4, 12 and 16

  42. Change From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Sodium, Potassium, Glucose, Urea Nitrogen, Calcium, Phosphate, Bicarbonate, Magnesium and Chloride

    Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.

    Time frame: From baseline to Weeks 2, 4, 8, 12 and 16

  43. Change From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Creatinine and Bilirubin

    Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.

    Time frame: From baseline to Weeks 2, 4, 8, 12 and 16

  44. Change From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Creatinine Kinase, Alkaline Phosphatase, Aspartate Aminotransferase, Alanine Aminotransferase and Gamma Glutamyl Transferase

    Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.

    Time frame: From baseline to Weeks 2, 4, 8, 12 and 16

  45. Change From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Protein and Albumin

    Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.

    Time frame: From baseline to Weeks 2, 4, 8, 12 and 16

  46. Change From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Hemoglobin A1C

    Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.

    Time frame: From baseline to Weeks 2, 4, 8, 12 and 16

  47. Change From Baseline at Weeks 12 and 16 in Clinical Laboratory Parameters Bone: Bone Specific Alkaline Phosphatase and Procollagen 1 N-Terminal Propeptide

    Blood for assessment of bone turnover markers was collected and sent to the central laboratory for analysis.

    Time frame: From baseline to Weeks 12 and 16

  48. Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: pH

    Urine for urinalysis was collected and sent to the central laboratory for analysis. Urine pH was measured on a pH scale.

    Time frame: From baseline to Weeks 2, 4, 12 and 16

  49. Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Specific Gravity

    Urine for urinalysis was collected and sent to the central laboratory for analysis.

    Time frame: From baseline to Weeks 2, 4, 12 and 16

  50. Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Glucose, Bilirubin, Ketones, Occult Blood, Protein, Urobilinogen and Nitrite

    Urine for urinalysis was collected and sent to the central laboratory for analysis. Clinical relevance was judged by the investigator. Assessment was done using standard laboratory practice. For evaluation of the chemical properties of the urine sample test strips were used which have test pads of chemicals that change color when they come in contact with reagents. The degree of color change correlates with the amount of reagent present. Each color block represents a range of values. Range and direction of scores for reagents nitrite and urobilinogen: negative = normal; positive = abnormal. Range and direction of scores for all other reagents tested: negative = normal; trace, 1+, 2+, 3+ = abnormal, the higher the value, the higher the concentration of the reagent tested.

    Time frame: From baseline to Weeks 2, 4, 12 and 16

  51. Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Erythrocytes and Leukocytes

    Urine for urinalysis was collected and sent to the central laboratory for analysis. Results are reported according to the amount present in the microscope's field of view at high magnification (/HPF \[high-power field\]).

    Time frame: From baseline to Weeks 2, 4, 12 and 16

  52. Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Hyaline Casts

    Urine for urinalysis was collected and sent to the central laboratory for analysis. Results are reported according to the amount present in the microscope's field of view at low magnification (/LPF \[low-power field\]).

    Time frame: From baseline to Weeks 2, 4, 12 and 16

  53. Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Bacteria, Yeast Cells, Granular Casts, RBC Casts, Waxy Casts, WBC Casts, Calcium Oxalate Crystals, Triple Phosphate Crystals and Uric Acid Crystals

    Urine for urinalysis was collected and sent to the central laboratory for analysis. The evaluation of components in the urine samples such as bacteria, yeast, red blood cells (RBC), white blood cells (WBC), casts and crystals was performed by microscopy. Results are reported according to the amount present in the microscope's field of view at low magnification (/LPF \[low-power field\]) and high magnification (/HPF \[high-power field\]). Range and direction of scores microscopic identification of urine components: * Bacteria: none seen, 1+, 2+, 3+,4+, TNTC (too numerous to count). * Other urine components: none seen=normal; few, moderate, many, TNTC = abnormal. The higher the value, the higher the concentration of the component evaluated.

    Time frame: From baseline to Weeks 2, 4, 12 and 16

07

Results

Posted Mar 10, 2023

Participant flow

The study was conducted between 20 November 2018 (first participant, first visit) and 21 November 2019 (last participant, last visit) at 11 sites in the USA, nine sites in the UK, and five sites in Canada.

Participant flow — Overall Study
MilestonePlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Started4731175252
Completed4330165145
Not completed41117
Withdrew: Protocol violation00001
Withdrew: Adverse event20105
Withdrew: Withdrawal by subject21011

Outcome measures

PrimaryMean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 4

Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.

Time frame:
From baseline to Week 4
Reported as:
Mean · Hot flushes per day
Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 4
Hot flushes per dayPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline11.82 ± 4.4212.13 ± 8.8114.55 ± 5.8713.54 ± 7.1712.92 ± 6.90
Week 4: Change from baseline-2.45 ± 3.65-4.19 ± 5.78-4.30 ± 6.45-6.76 ± 5.85-5.42 ± 5.36
Statistical analysis
  • Placebo vs 40 mg Elinzanetant (BAY3427080) · Mixed-Effect Model Repeated Measures · p = = 0.1946 · Difference in ls means: -1.52 · 95% CI -3.83 to 0.78
  • Placebo vs 80 mg Elinzanetant (BAY3427080) · Mixed-Effect Model Repeated Measures · p = = 0.3682 · Difference in ls means: 1.29 · 95% CI -4.11 to 1.53
  • Placebo vs 120 mg Elinzanetant (BAY3427080) · Mixed-Effect Model Repeated Measures · p = = 0.0002 · Difference in ls means: -3.93 · 95% CI -5.94 to -1.92
  • Placebo vs 160 mg Elinzanetant (BAY3427080) · Mixed-Effect Model Repeated Measures · p = = 0.0115 · Difference in ls means: -2.63 · 95% CI -4.66 to -0.6
PrimaryMean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 12

Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.

Time frame:
From baseline to Week 12
Reported as:
Mean · Hot flushes per day
Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 12
Hot flushes per dayPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline11.82 ± 4.4212.13 ± 8.8114.55 ± 5.8713.54 ± 7.1712.92 ± 6.90
Week 12: Change from baseline-4.49 ± 4.29-6.48 ± 7.82-5.49 ± 5.31-7.91 ± 6.66-6.57 ± 5.83
Statistical analysis
  • Placebo vs 40 mg Elinzanetant (BAY3427080) · Mixed-Effect Model Repeated Measures · p = = 0.2097 · Difference in ls means: -1.67 · 95% CI -4.28 to -0.95
  • Placebo vs 80 mg Elinzanetant (BAY3427080) · Mixed-Effect Model Repeated Measures · p = = 0.6369 · Difference in ls means: -0.77 · 95% CI -3.97 to 2.44
  • Placebo vs 120 mg Elinzanetant (BAY3427080) · Mixed-Effect Model Repeated Measures · p = = 0.0116 · Difference in ls means: -2.95 · 95% CI -5.22 to -0.67
  • Placebo vs 160 mg Elinzanetant (BAY3427080) · Mixed-Effect Model Repeated Measures · p = = 0.1346 · Difference in ls means: -1.78 · 95% CI -4.12 to 0.56
PrimaryMean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 4

Participants recorded daily in their eDiary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).

Time frame:
From baseline to Week 4
Reported as:
Mean · Hot flushes per day
Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 4
Hot flushes per dayPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline2.54 ± 0.202.51 ± 0.262.63 ± 0.242.54 ± 0.242.54 ± 0.26
Week 4: Change from baseline-0.31 ± 0.41-0.38 ± 0.54-0.44 ± 0.56-0.51 ± 0.57-0.54 ± 0.67
Statistical analysis
  • Placebo vs 40 mg Elinzanetant (BAY3427080) · Mixed-Effect Model Repeated Measures · p = = 0.7033 · Difference in ls means: -0.05 · 95% CI -0.3 to 0.2
  • Placebo vs 80 mg Elinzanetant (BAY3427080) · Mixed-Effect Model Repeated Measures · p = = 0.3724 · Difference in ls means: -0.14 · 95% CI -0.45 to 0.17
  • Placebo vs 120 mg Elinzanetant (BAY3427080) · Mixed-Effect Model Repeated Measures · p = = 0.0896 · Difference in ls means: -0.19 · 95% CI -0.41 to 0.03
  • Placebo vs 160 mg Elinzanetant (BAY3427080) · Mixed-Effect Model Repeated Measures · p = = 0.09 · Difference in ls means: -0.19 · 95% CI -0.41 to 0.03
PrimaryMean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 12

Participants recorded daily in their eDiary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity was graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).

Time frame:
From baseline to Week 12
Reported as:
Mean · Hot flushes per day
Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 12
Hot flushes per dayPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline2.54 ± 0.202.51 ± 0.262.63 ± 0.242.54 ± 0.242.54 ± 0.26
Week 12: Change from baseline-0.41 ± 0.50-0.53 ± 0.64-0.26 ± 0.45-0.56 ± 0.68-0.73 ± 0.78
Statistical analysis
  • Placebo vs 40 mg Elinzanetant (BAY3427080) · Mixed-Effect Model Repeated Measures · p = = 0.5511 · Difference in ls means: -0.09 · 95% CI -0.39 to 0.21
  • Placebo vs 80 mg Elinzanetant (BAY3427080) · Mixed-Effect Model Repeated Measures · p = = 0.3822 · Difference in ls means: 0.16 · 95% CI -0.2 to 0.52
  • Placebo vs 120 mg Elinzanetant (BAY3427080) · Mixed-Effect Model Repeated Measures · p = = 0.2606 · Difference in ls means: -0.15 · 95% CI -0.41 to 0.11
  • Placebo vs 160 mg Elinzanetant (BAY3427080) · Mixed-Effect Model Repeated Measures · p = = 0.0479 · Difference in ls means: -0.27 · 95% CI -0.53 to 0
SecondaryMean Change From Baseline in Frequency of Mean Daily Moderate and Severe Hot Flushes From Baseline to Weeks 1, 2, 8 and 16

Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.

Time frame:
From baseline to Weeks 1, 2, 8 and 16
Reported as:
Mean · Hot flushes per day
Mean Change From Baseline in Frequency of Mean Daily Moderate and Severe Hot Flushes From Baseline to Weeks 1, 2, 8 and 16
Hot flushes per dayPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline11.82 ± 4.4212.13 ± 8.8114.55 ± 5.8713.54 ± 7.1712.92 ± 6.90
Week 1: Change from baseline-1.22 ± 3.07-1.61 ± 3.05-1.63 ± 3.56-3.22 ± 3.43-3.09 ± 3.76
Week 2: Change from baseline-2.19 ± 4.01-3.03 ± 3.95-3.47 ± 4.37-4.58 ± 4.70-3.78 ± 4.48
Week 8: Change from baseline-4.33 ± 4.79-5.72 ± 6.18-5.94 ± 5.26-7.84 ± 5.95-5.58 ± 6.00
Week 16: Change from baseline-3.95 ± 4.85-5.74 ± 9.45-2.01 ± 4.99-5.95 ± 6.95-2.78 ± 6.54
SecondaryMean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Weeks 1, 2, 8 and 16

Participants recorded daily in their diary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).

Time frame:
From baseline to Weeks 1, 2, 8 and 16
Reported as:
Mean · Hot flushes per day
Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Weeks 1, 2, 8 and 16
Hot flushes per dayPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline2.54 ± 0.202.51 ± 0.262.63 ± 0.242.54 ± 0.242.55 ± 0.26
Week 1: Change from baseline-0.24 ± 0.30-0.21 ± 0.20-0.22 ± 0.21-0.25 ± 0.28-0.26 ± 0.26
Week 2: Change from baseline-0.30 ± 0.39-0.32 ± 0.32-0.42 ± 0.58-0.37 ± 0.46-0.40 ± 0.55
Week 8: Change from baseline-0.45 ± 0.58-0.48 ± 0.54-0.40 ± 0.61-0.51 ± 0.54-0.65 ± 0.73
Week 16: Change from baseline2.15 ± 0.652.03 ± 0.562.50 ± 0.462.13 ± 0.712.08 ± 0.62
SecondaryMean Change From Baseline in Mean Daily Frequency of All Hot Flushes From Baseline to Weeks 1, 2, 4, 8, 12 and 16

Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.

Time frame:
From baseline to Weeks 1, 2, 4, 8, 12 and 16
Reported as:
Mean · Hot flushes per day
Mean Change From Baseline in Mean Daily Frequency of All Hot Flushes From Baseline to Weeks 1, 2, 4, 8, 12 and 16
Hot flushes per dayPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline14.04 ± 5.5714.19 ± 11.0116.55 ± 6.8915.39 ± 7.9115.78 ± 9.62
Week 1-1.36 ± 3.03-1.72 ± 3.27-1.33 ± 5.68-3.30 ± 3.99-3.69 ± 4.81
Week 2-2.35 ± 4.60-2.99 ± 4.90-2.74 ± 5.97-4.57 ± 5.48-4.43 ± 5.68
Week 4-2.67 ± 4.09-4.11 ± 6.31-3.45 ± 8.54-6.70 ± 6.16-5.79 ± 6.09
Week 8-4.74 ± 5.57-5.65 ± 6.55-5.45 ± 6.56-7.96 ± 6.16-6.03 ± 6.43
Week 12-5.07 ± 5.48-6.50 ± 8.67-5.11 ± 8.41-7.94 ± 6.74-7.47 ± 7.13
Week 16-4.60 ± 6.17-5.83 ± 10.86-1.76 ± 7.50-6.19 ± 7.68-3.11 ± 6.71
SecondaryMean Change From Baseline in Mean Severity of All Hot Flushes From Baseline to Weeks 1, 2, 4, 8, 12 and 16

Participants recorded daily in their diary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).

Time frame:
From baseline to Weeks 1, 2, 4, 8, 12 and 16
Reported as:
Mean · Hot flushes per day
Mean Change From Baseline in Mean Severity of All Hot Flushes From Baseline to Weeks 1, 2, 4, 8, 12 and 16
Hot flushes per dayPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline2.34 ± 0.322.34 ± 0.352.46 ± 0.372.38 ± 0.342.35 ± 0.39
Week 1: Change from baseline-0.04 ± 0.23-0.04 ± 0.18-0.05 ± 0.12-0.09 ± 0.25-0.07 ± 0.18
Week 2: Change from baseline-0.10 ± 0.32-0.15 ± 0.27-0.25 ± 0.52-0.21 ± 0.46-0.20 ± 0.50
Week 4: Change from baseline-0.11 ± 0.36-0.21 ± 0.47-0.27 ± 0.49-0.35 ± 0.60-0.34 ± 0.63
Week 8: Change from baseline-0.25 ± 0.54-0.31 ± 0.47-0.23 ± 0.52-0.35 ± 0.55-0.44 ± 0.72
Week 12: Change from baseline-0.21 ± 0.44-0.35 ± 0.57-0.08 ± 0.41-0.41 ± 0.62-0.52 ± 0.79
Week 16: Change from baseline-0.21 ± 0.49-0.30 ± 0.520.05 ± 0.34-0.26 ± 0.56-0.24 ± 0.54
SecondaryMean Change From Baseline in the Mean Daily Hot Flush Score (Frequency x Severity) at Weeks 1, 2, 4, 8, 12 and 16

Mean daily Hot Flushes score = Sum of (frequency x severity) filled in the diary during the last 7 days (with at least one available data in the evening and/or morning) divided by 7. Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).

Time frame:
From baseline to Weeks 1, 2, 4, 8, 12 and 16
Reported as:
Mean · (units on a scale)*(hot flushes per day)
Mean Change From Baseline in the Mean Daily Hot Flush Score (Frequency x Severity) at Weeks 1, 2, 4, 8, 12 and 16
(units on a scale)*(hot flushes per day)Placebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline32.35 ± 12.2432.84 ± 24.8240.76 ± 17.0836.59 ± 19.8835.73 ± 19.75
Week 1: Change from baseline-3.09 ± 8.16-4.26 ± 7.93-4.18 ± 11.27-8.44 ± 8.98-8.67 ± 10.53
Week 2: Change from baseline-5.62 ± 11.00-7.88 ± 10.77-9.08 ± 13.09-11.98 ± 12.39-10.51 ± 12.47
Week 4: Change from baseline-6.62 ± 9.79-10.68 ± 15.26-11.39 ± 18.82-17.54 ± 15.50-14.20 ± 14.30
Week 8: Change from baseline-11.63 ± 12.51-14.64 ± 16.33-16.17 ± 15.32-20.54 ± 15.80-14.89 ± 15.36
Week 12: Change from baseline-12.33 ± 11.96-16.71 ± 20.60-14.93 ± 16.83-20.72 ± 17.81-17.70 ± 15.38
Week 16: Change from baseline-10.89 ± 13.45-14.93 ± 25.48-4.97 ± 14.35-15.60 ± 19.03-7.50 ± 16.55
SecondaryNumber of Participants With ≥50% and ≥80% Reduction From Baseline in Mean Daily Hot Flushes Frequency at Week 12

The percent change from baseline at a visit Week 12 was calculated. Percent change = (change from baseline in mean daily frequency of moderate and severe hot flushes from baseline to Week 12 / Mean daily frequency of moderate and severe hot flushes at baseline) \* 100. A participant was considered as a responder with a reduction of ≥50% (or ≥80%) if the percent change was ≤-50 (or ≤-80).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants With ≥50% and ≥80% Reduction From Baseline in Mean Daily Hot Flushes Frequency at Week 12
ParticipantsPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
>= 50% reduction — Yes172053230
>= 50% reduction — No2710111913
>=80% reduction — Yes8601618
>=80% reduction — No3624163525
SecondaryMean Change From Baseline in Number of All Night-time Awakenings (NTA) at Weeks 1, 2, 4, 8, 12 and 16

Participants were provided with an eDiary to document the number of night-time awakenings (NTA). Each evening, participants recorded the total number of hot flushes of each severity experienced that day since waking. Each morning upon waking, subjects recorded the number of times they woke up in the night and the total number of hot flushes of each severity experienced during the night.

Time frame:
From baseline to Weeks 1, 2, 4, 8, 12 and 16
Reported as:
Mean · Night-time awakenings per day
Mean Change From Baseline in Number of All Night-time Awakenings (NTA) at Weeks 1, 2, 4, 8, 12 and 16
Night-time awakenings per dayPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline3.86 ± 2.063.44 ± 1.825.00 ± 1.763.80 ± 2.203.85 ± 2.57
Week 1: Change from baseline-0.65 ± 1.08-0.70 ± 1.24-0.57 ± 1.57-0.91 ± 1.06-0.86 ± 1.93
Week 2: Change from baseline-0.62 ± 1.54-0.70 ± 1.20-1.09 ± 1.84-1.10 ± 1.34-1.00 ± 2.10
Week 4: Change from baseline-0.86 ± 1.40-1.05 ± 1.43-0.99 ± 2.96-1.49 ± 1.43-1.03 ± 2.22
Week 8: Change from baseline-0.99 ± 1.31-1.66 ± 1.77-1.30 ± 2.15-1.79 ± 1.47-1.17 ± 2.51
Week 12: Change from baseline-1.28 ± 1.44-1.53 ± 1.89-1.61 ± 2.46-1.60 ± 1.38-1.40 ± 2.40
Week 16: Change from baseline-1.08 ± 1.30-0.96 ± 1.91-0.31 ± 2.90-1.05 ± 1.30-0.32 ± 2.10
SecondaryMean Change From Baseline in Mean Daily Number of NTAs Secondary to Hot Flushes at Weeks 1, 2, 4, 8, 12 and 16

Subjects were provided with an eDiary to document the number of night-time awakenings (NTA). Each evening, subjects recorded the total number of hot flashes of each severity experienced that day since waking. Each morning upon waking, subjects recorded the number of times they woke up in the night and the total number of hot flushes of each severity experienced during the night. Night-time awakenings secondary to hot flashes corresponded to severe hot flash recorded on the morning diary, and all NTAs corresponded to the data recorded in the "Total number of times you woke up last night?" field from the eDiary recorded in the morning. Number of NTAs secondary to hot flushes could not be higher than the number of all NTAs.

Time frame:
From baseline to Weeks 1, 2, 4, 8, 12 and 16
Reported as:
Mean · Night-time awakenings per day
Mean Change From Baseline in Mean Daily Number of NTAs Secondary to Hot Flushes at Weeks 1, 2, 4, 8, 12 and 16
Night-time awakenings per dayPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline2.90 ± 1.642.41 ± 1.574.05 ± 1.862.76 ± 1.712.57 ± 1.54
Week 1: Change from baseline-0.57 ± 0.96-0.52 ± 1.07-0.63 ± 1.53-0.90 ± 1.03-0.68 ± 1.14
Week 2: Change from baseline-0.69 ± 1.03-0.75 ± 1.18-1.13 ± 1.89-1.18 ± 1.27-0.92 ± 1.38
Week 4: Change from baseline-0.89 ± 1.08-0.91 ± 1.26-1.33 ± 2.27-1.53 ± 1.19-1.01 ± 1.62
Week 8: Change from baseline-1.09 ± 1.36-1.50 ± 1.40-1.69 ± 2.21-1.79 ± 1.35-1.13 ± 1.86
Week 12: Change from baseline-1.31 ± 1.39-1.63 ± 1.46-1.70 ± 2.53-1.67 ± 1.27-1.32 ± 1.75
Week 16: Change from baseline-1.05 ± 1.19-1.29 ± 1.63-0.45 ± 2.05-1.19 ± 1.23-0.44 ± 1.62
SecondaryChange From Baseline in the Global and Individual Domain Scores of the Pittsburgh Sleep Quality Index (PSQI) at Weeks 4, 8, 12 and 16

The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. The PSQI uses 19 individual items to generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction, each scored 0 (no difficulty) to 3 (severe difficulty). The sum of scores for these seven components yields one global score (range 0 to 21). Higher scores indicated worse sleep quality.

Time frame:
From baseline to Weeks 4, 8, 12 and 16
Reported as:
Mean · Units on scale
Change From Baseline in the Global and Individual Domain Scores of the Pittsburgh Sleep Quality Index (PSQI) at Weeks 4, 8, 12 and 16
Units on scalePlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline10.80 ± 2.3911.94 ± 3.1111.35 ± 3.6610.80 ± 3.0011.44 ± 3.14
Week 4: Change from baseline-0.63 ± 2.02-1.87 ± 2.93-1.94 ± 2.68-2.70 ± 3.11-2.80 ± 2.84
Week 8: Change from baseline-1.36 ± 2.90-2.39 ± 3.63-2.38 ± 3.30-3.00 ± 3.23-3.14 ± 3.37
Week 12: Change from baseline-1.15 ± 2.95-2.47 ± 3.82-2.81 ± 2.97-3.39 ± 3.12-3.54 ± 4.12
Week 16: Change from baseline-1.85 ± 2.46-2.10 ± 3.53-1.38 ± 3.26-2.24 ± 3.12-1.79 ± 2.69
SecondaryChange From Baseline in the Insomnia Severity Index (ISI) Score at Weeks 4, 8, 12 and 16

The ISI is a brief self-report questionnaire assessing the nature, severity, and impact of insomnia. The ISI comprises seven items assessing the perceived severity of difficulties initiating sleep, staying asleep, and early morning awakenings, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and degree of distress or concern caused by the sleep problem. Participants rated each item on a scale of 0 to 4, yielding a total score ranging from 0 to 28. The total score was calculated by adding the scores for all seven items. Higher scores indicated severe insomnia.

Time frame:
From baseline to Weeks 4, 8, 12 and 16
Reported as:
Mean · Units on scale
Change From Baseline in the Insomnia Severity Index (ISI) Score at Weeks 4, 8, 12 and 16
Units on scalePlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline12.43 ± 5.0913.23 ± 5.3613.24 ± 8.0412.63 ± 5.6613.74 ± 5.89
Week 4: Change from Baseline-1.60 ± 2.98-2.74 ± 4.91-3.65 ± 6.03-5.14 ± 5.51-5.42 ± 5.42
Week 8: Change from Baseline-1.51 ± 3.64-3.74 ± 5.63-4.44 ± 6.17-6.20 ± 4.93-5.72 ± 5.14
Week 12: Change from Baseline-1.95 ± 4.70-3.80 ± 5.45-5.81 ± 5.86-6.12 ± 5.41-7.39 ± 5.82
Week 16: Change from Baseline-2.65 ± 4.32-3.73 ± 6.02-3.00 ± 3.72-4.34 ± 5.58-4.00 ± 5.49
SecondaryChange From Baseline in the Hot Flush Related Daily Interference Scale (HFRDIS) Scores at Weeks 2, 4, 8, 12 and 16

The HFRDIS is a 10-item, self-report questionnaire assessing the impact of hot flushes on a woman's life during the past week. For each of the 10 items, participants rated how much hot flushes had interfered with that aspect of their life on a scale of 0 (not at all) to 10 (very much so). The total score was calculated by adding the scores for all 10 items. Higher scores indicated greater interference.

Time frame:
From baseline to Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · Units on scale
Change From Baseline in the Hot Flush Related Daily Interference Scale (HFRDIS) Scores at Weeks 2, 4, 8, 12 and 16
Units on scalePlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline52.93 ± 18.4052.74 ± 20.3350.29 ± 21.4553.86 ± 23.4255.36 ± 19.71
Week 2: Change from baseline-4.00 ± 20.28-5.39 ± 21.99-11.12 ± 28.14-13.75 ± 29.66-10.90 ± 21.31
Week 4: Change from baseline-9.98 ± 20.84-13.00 ± 22.53-15.06 ± 24.02-23.04 ± 28.32-18.44 ± 23.37
Week 8: Change from baseline-15.48 ± 21.07-16.26 ± 23.71-17.88 ± 27.15-26.39 ± 24.90-24.09 ± 25.51
Week 12: Change from-19.37 ± 20.20-21.30 ± 22.89-15.56 ± 28.70-28.33 ± 25.36-27.83 ± 24.64
Week 16: Change from baseline-15.22 ± 21.72-10.73 ± 24.87-16.69 ± 24.15-19.16 ± 22.43-12.07 ± 25.94
SecondaryChange From Baseline in the Menopause-specific Quality-of-Life Questionnaire Intervention Version (MenQoL-I) Scores at Weeks 4, 8, 12 and 16

The MenQoL-I is a validated questionnaire used to measure condition-specific quality of life in menopausal women. It is composed of 32 items across four domains (physical, vasomotor, psychosocial and sexual). For each item, participants recorded whether they had experienced the problem in the past month, and if so, they rated how bothered they were by the problem on a scale of 0 (not at all bothered) to 6 (extremely bothered). The item scores were converted to a score ranging from 1 to 8. Domain scores are calculated by averaging the converted individual item scores (range 1-8) related to the respective domain. (Domains: Vasomotor - items 1 to 3, Psychosocial - items 4 to 10, Physical- items 11- to 26, Sexual - items 27 to 29). For a MENQOL total score the aggregated mean of the mean domain scores is calculated. Higher scores indicate greater bother.

Time frame:
From baseline to Weeks 4, 8, 12 and 16;
Reported as:
Mean · Units on scale
Change From Baseline in the Menopause-specific Quality-of-Life Questionnaire Intervention Version (MenQoL-I) Scores at Weeks 4, 8, 12 and 16
Units on scalePlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline4.00 ± 1.064.38 ± 1.164.47 ± 1.254.17 ± 1.134.50 ± 1.23
Week 4: Change from baseline-0.33 ± 0.90-0.62 ± 1.30-0.56 ± 0.87-1.29 ± 1.14-1.13 ± 1.09
Week 8: Change from baseline-0.62 ± 1.10-0.87 ± 1.25-0.91 ± 1.06-1.45 ± 1.18-1.50 ± 0.99
Week 12: Change from baseline-0.70 ± 1.03-0.81 ± 1.44-1.09 ± 0.76-1.54 ± 1.34-1.72 ± 1.32
Week 16: Change from baseline-0.68 ± 1.01-0.76 ± 1.33-0.69 ± 0.93-1.18 ± 1.13-1.00 ± 1.36
SecondaryChange From Baseline in the Beck Depression Inventory II (BDI-II) Scores at Weeks 2, 4, 8, 12 and 16

The BDI-II is a 21-item questionnaire assessing the intensity of depressive symptoms over the past 2 weeks. It is composed of items relating to symptoms of depression such as hopelessness and irritability, cognitions such as guilt or feelings of being punished, as well as physical symptoms such as fatigue, weight loss, and lack of interest in sex. Participants rated each item on a scale of 0 to 3 to give a total score ranging from 0 to 63, with a higher score suggesting more severe depressive symptoms.

Time frame:
From baseline to Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · Units on scale
Change From Baseline in the Beck Depression Inventory II (BDI-II) Scores at Weeks 2, 4, 8, 12 and 16
Units on scalePlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline11.18 ± 8.7414.29 ± 11.3610.47 ± 7.019.92 ± 8.6211.48 ± 9.30
Week 2: Change from baseline-1.90 ± 5.29-2.23 ± 9.27-3.06 ± 7.34-3.65 ± 6.95-2.71 ± 6.08
Week 4: Change from baseline-1.55 ± 5.14-4.23 ± 9.82-2.35 ± 5.16-4.08 ± 6.39-4.13 ± 6.63
Week 8: Change from baseline-2.24 ± 5.26-5.32 ± 10.13-2.00 ± 8.22-4.73 ± 6.34-5.51 ± 7.14
Week 12: Change from baseline-1.30 ± 7.22-5.00 ± 3.80-1.69 ± 7.65-4.29 ± 6.56-5.73 ± 7.39
Week 16: Change from baseline-2.43 ± 6.08-5.10 ± 11.62-0.75 ± 6.71-4.04 ± 6.12-2.36 ± 8.05
SecondaryPlasma Elinzanetant Concentrations at Weeks 2, 4, 8 ,12

Blood samples for analysis of plasma elinzanetant concentrations were collected at Weeks 2, 4, 8, and 12. A small number of participants had elinzanetant concentrations below the LOQ for the assay (1.5 ng/mL) at two or more visits (three participants in each of the 40 mg, 120 mg, and 160 mg groups, four in 80 mg group), indicating that these subjects were non compliant with treatment.

Time frame:
At Weeks 2, 4, 8 ,12
Reported as:
Geometric mean · ng/ml
Plasma Elinzanetant Concentrations at Weeks 2, 4, 8 ,12
ng/ml40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Week 264.254 ± 75.681157.207 ± 93.120292.929 ± 100.381319.552 ± 170.571
Week 478.946 ± 78.892118.554 ± 175.865253.800 ± 142.944398.389 ± 91.644
Week 887.985 ± 68.277138.795 ± 72.619226.121 ± 79.171341.673 ± 145.535
Week 1270.138 ± 66.542130.729 ± 414.199197.041 ± 231.390298.896 ± 220.963
SecondaryNature and Severity of Adverse Events

A Treatment-Emergent Adverse Events (TEAE) is defined as any adverse event (serious and non-serious) with the onset date on or after the date of first dosing with study treatment. Safety Analysis Set.

Time frame:
Up to Week 16
Reported as:
Count of participants · Participants
Nature and Severity of Adverse Events
ParticipantsPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Number of TEAEs2817143438
Number of TEAEs related to IMP778812
Number of Serious TEAEs20111
Number of TEAEs leading to death00000
Number of Severe TEAEs20132
SecondaryWithdrawals Due to an Adverse Event

A Treatment-Emergent Adverse Events (TEAE) is defined as any adverse event (serious and non-serious) with the onset date on or after the date of first dosing with study treatment.

Time frame:
Up to Week 16
Reported as:
Count of participants · Participants
Withdrawals Due to an Adverse Event
ParticipantsPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
TEAEs leading to treatment discontinuation10205
TEAEs leading to study discontinuation10104
SecondaryNumber of Subjects Used Concomitant Medications

A concomitant medication is defined as any medication used on or after date and time of first randomised treatment. All concomitant medications taken during the study were recorded in the eCRF. Any medication that was not specifically prohibited was allowed. (1) Antidiarrheals, intestinal antiinflammatory/antiinfective agents.

Time frame:
Up to Week 16
Reported as:
Count of participants · Participants
Number of Subjects Used Concomitant Medications
ParticipantsPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Analgesics18891216
Antiinflammatory and antirheumatic products14751213
Vitamins1466914
Drugs for acid related disorders13721010
Psychoanaleptics654109
Psycholeptics37577
Antibacterials for systemic use95257
Drugs for obstructive airway diseases73349
Lipid modifying agents33484
Agents acting on the renin-angiotensin system740113
Thyroid therapy43375
Antihistamines for systemic use54363
Antithrombotic agents24264
Nasal preparations24117
Diuretics12055
Antianemic preparations52252
Mineral supplements22333
Calcium channel blockers30163
Drugs used in diabetes32016
Beta blocking agents12051
Ophthalmologicals11231
Urologicals11131
Antidiarrheals, intestinal agents (1)22003
Antivirals for systemic use13110
Corticosteroids for systemic use11013
Drugs for constipation20131
Anesthetics21030
Antiemetics and antinauseants20112
Drugs for functional gastrointestinal disorders31012
General nutrients11012
Topical products for joint and muscular pain12002
Antifungals for dermatological use01101
Antiobesity preparations, excl. Diet products00021
Corticosteroids, dermatological preparations12010
Cough and cold preparations31020
Other nervous system drugs11011
Unspecified herbal and traditional medicine10111
All other therapeutic products00010
Anti-acne preparations01010
Other alimentary tract and metabolism products11010
Throat preparations01001
Vaccines01010
Antiepileptics00100
Antihemorrhagics00001
Antihypertensives00100
Antiprotozoals00001
Antipruritics, incl. antihistamines, anesthetics00001
Antipsoriatics00001
Bile and liver therapy00010
Drugs for treatment of bone diseases00100
Gynecological antiinfectives and antiseptics00010
Immunosuppressants00010
Other respiratory system products00001
Stomatological preparations00001
Tonics00010
Muscle relaxants20112
Antibiotics,chemotherapeutics (dermatological use)10010
Antimycotics for systemic use10000
SecondaryChange From Baseline in Vital Signs (Systolic Blood Pressure) at Weeks 2, 4, 8, 12 and 16

Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.

Time frame:
From baseline to Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · mmHg
Change From Baseline in Vital Signs (Systolic Blood Pressure) at Weeks 2, 4, 8, 12 and 16
mmHgPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline123.2 ± 10.4124.2 ± 10.1128.9 ± 9.8124.6 ± 10.9124.0 ± 12.9
Week 2: Change from baseline0.3 ± 12.5-0.2 ± 9.0-1.5 ± 12.5-2.9 ± 9.3-0.8 ± 9.2
Week 4: Change from baseline1.7 ± 12.40.1 ± 11.9-3.1 ± 9.4-4.7 ± 10.7-1.3 ± 10.8
Week 8: Change from baseline0.5 ± 10.80.5 ± 12.5-2.1 ± 10.1-1.3 ± 10.0-3.8 ± 10.5
Week 12: Change from baseline-0.6 ± 12.2-2.1 ± 10.9-5.9 ± 11.3-1.1 ± 10.2-1.3 ± 12.8
Week 16: Change from baseline3.8 ± 13.3-0.9 ± 11.7-6.4 ± 11.1-1.4 ± 10.82.1 ± 9.4
SecondaryChange From Baseline in Vital Signs (Diastolic Blood Pressure) at Weeks 2, 4, 8, 12 and 16

Vital signs, including systolic and diastolic blood pressure were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.

Time frame:
From baseline to Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · mmHg
Change From Baseline in Vital Signs (Diastolic Blood Pressure) at Weeks 2, 4, 8, 12 and 16
mmHgPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline80.1 ± 8.078.7 ± 8.579.9 ± 9.178.1 ± 7.678.7 ± 10.1
Week 2: Change from baseline-0.7 ± 6.6-1.1 ± 8.4-0.8 ± 8.7-3.1 ± 7.6-0.4 ± 7.6
Week 4: Change from baseline-0.2 ± 7.41.2 ± 7.8-2.1 ± 6.5-2.8 ± 9.1-2.3 ± 8.0
Week 8: Change from baseline0.2 ± 6.7-0.5 ± 6.8-3.6 ± 6.9-0.6 ± 8.4-1.6 ± 7.5
Week 12: Change from baseline-0.5 ± 9.6-2.8 ± 9.9-2.2 ± 7.1-1.8 ± 10.3-1.0 ± 9.3
Week 16: Change from baseline1.6 ± 7.6-1.2 ± 8.3-3.8 ± 9.7-1.9 ± 9.10.6 ± 7.2
SecondaryChange From Baseline in Vital Signs (Pulse Rate) at Weeks 2, 4, 8, 12 and 16

Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.

Time frame:
From baseline to Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · beats/min
Change From Baseline in Vital Signs (Pulse Rate) at Weeks 2, 4, 8, 12 and 16
beats/minPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline69.7 ± 7.871.4 ± 10.370.6 ± 8.770.1 ± 10.269.7 ± 10.2
Week 2: Change from baseline-0.1 ± 8.1-0.3 ± 7.3-0.7 ± 9.9-3.1 ± 9.72.1 ± 9.4
Week 4: Change from baseline-0.6 ± 6.90.5 ± 7.6-2.8 ± 8.9-1.8 ± 6.40.9 ± 7.7
Week 8: Change from baseline0.4 ± 7.7-0.5 ± 8.1-3.1 ± 9.8-2.8 ± 7.90.3 ± 8.1
Week 12: Change from baseline0.1 ± 9.20.3 ± 8.40.9 ± 8.8-1.4 ± 8.80.9 ± 7.4
Week 16: Change from baseline3.2 ± 10.63.3 ± 10.50.0 ± 11.3-0.7 ± 8.50.3 ± 8.4
SecondaryChange From Baseline in Vital Signs (Temperature) at Weeks 2, 4, 8, 12 and 16

Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.

Time frame:
From baseline to Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · Celsius (C)
Change From Baseline in Vital Signs (Temperature) at Weeks 2, 4, 8, 12 and 16
Celsius (C)Placebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline36.69 ± 0.4336.62 ± 0.3236.73 ± 0.3036.52 ± 0.4636.68 ± 0.39
Week 2: Change from baseline-0.09 ± 0.40-0.04 ± 0.280.04 ± 0.260.12 ± 0.50-0.01 ± 0.43
Week 4: Change from baseline-0.15 ± 0.47-0.06 ± 0.340.01 ± 0.410.12 ± 0.46-0.06 ± 0.32
Week 8: Change from baseline-0.09 ± 0.38-0.01 ± 0.350.00 ± 0.310.11 ± 0.49-0.01 ± 0.42
Week 12: Change from baseline-0.12 ± 0.44-0.12 ± 0.31-0.03 ± 0.380.04 ± 0.46-0.08 ± 0.36
Week 16: Change from baseline-0.07 ± 0.50-0.03 ± 0.30-0.04 ± 0.320.08 ± 0.41-0.09 ± 0.41
SecondaryChange From Baseline in Vital Signs (Weight) at Weeks 2, 4, 8, 12 and 16

Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.

Time frame:
From baseline to Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · Kilogram (Kg)
Change From Baseline in Vital Signs (Weight) at Weeks 2, 4, 8, 12 and 16
Kilogram (Kg)Placebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline75.85 ± 13.1372.65 ± 14.7678.14 ± 15.7572.36 ± 15.2674.11 ± 15.02
Week 2: Change from baseline0.20 ± 1.070.30 ± 1.030.13 ± 1.32-0.13 ± 1.190.04 ± 0.84
Week 4: Change from baseline0.23 ± 1.510.08 ± 1.110.12 ± 1.88-0.31 ± 1.260.00 ± 1.35
Week 8: Change from baseline0.16 ± 1.980.26 ± 1.59-0.11 ± 1.79-0.18 ± 1.78-0.25 ± 2.32
Week 12: Change from baseline-0.02 ± 2.340.58 ± 2.46-0.14 ± 2.03-0.08 ± 1.93-0.48 ± 2.62
Week 16: Change from baseline0.17 ± 2.480.39 ± 2.81-0.13 ± 2.59-0.20 ± 2.13-0.34 ± 2.82
SecondaryChange From Baseline in Vital Signs (Body Mass Index ) at Weeks 2, 4, 8, 12 and 16

Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.

Time frame:
From baseline to Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · kg/m^2
Change From Baseline in Vital Signs (Body Mass Index ) at Weeks 2, 4, 8, 12 and 16
kg/m^2Placebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline28.59 ± 3.8127.69 ± 4.9729.81 ± 4.9327.26 ± 4.8527.72 ± 4.74
Week 2: Change from baseline0.07 ± 0.410.11 ± 0.390.06 ± 0.5-0.04 ± 0.450.01 ± 0.33
Week 4: Change from baseline0.07 ± 0.580.02 ± 0.420.06 ± 0.75-0.11 ± 0.490.00 ± 0.53
Week 8: Change from baseline0.04 ± 0.750.09 ± 0.59-0.04 ± 0.69-0.06 ± 0.66-0.09 ± 0.88
Week 12: Change from baseline-0.03 ± 0.870.21 ± 0.87-0.05 ± 0.79-0.02 ± 0.73-0.18 ± 0.99
Week 16: Change from baseline0.04 ± 0.960.13 ± 1.01-0.04 ± 1.01-0.07 ± 0.79-0.13 ± 1.07
SecondaryChange From Baseline in Vital Signs (Waist Circumference) at Weeks 2, 4, 8, 12 and 16

Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature, weight, waist circumference, and height, were measured at the time points and recorded in the eCRF. All vital signs were reviewed by the Investigator or delegated physician.

Time frame:
From baseline to Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · cm
Change From Baseline in Vital Signs (Waist Circumference) at Weeks 2, 4, 8, 12 and 16
cmPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline95.47 ± 11.6993.61 ± 13.1097.59 ± 13.1591.12 ± 13.0392.42 ± 12.36
Week 2: Change from baseline0.26 ± 3.990.79 ± 3.55-0.91 ± 2.150.13 ± 3.72-0.18 ± 3.90
Week 4: Change from baseline0.17 ± 4.99-0.07 ± 4.23-1.26 ± 3.000.05 ± 3.84-0.09 ± 3.97
Week 8: Change from baseline-0.14 ± 4.45-0.11 ± 4.300.04 ± 2.77-0.76 ± 4.10-0.08 ± 4.71
Week 12: Change from baseline-1.72 ± 5.25-1.16 ± 4.870.60 ± 2.81-0.25 ± 3.97-0.39 ± 4.42
Week 16: Change from baseline-0.80 ± 5.46-0.99 ± 5.184.33 ± 12.900.02 ± 4.58-0.24 ± 4.41
SecondaryNumber of Subjects With Normal Electrocardiogram (ECG) Findings at Each Visit

All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reported results are cardiovascular system-examination findings. Normal ECG was decided by investigator. The findings are presented as Normal ECG.

Time frame:
At Weeks 2, 4, 8, 12 and 16
Reported as:
Count of participants · Participants
Number of Subjects With Normal Electrocardiogram (ECG) Findings at Each Visit
ParticipantsPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline3824113134
Week 23323123427
Week 43223102831
Week 82921123027
Week 123022113131
Week 162726143128
SecondaryNumber of Subjects With Abnormal Not Clinically Significant ECG Findings at Each Visit

All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reported results are cardiovascular system-examination findings. Abnormal not clinically significant ECG findings were decided by investigator. The findings are presented as Abnormal not clinically significant ECG.

Time frame:
At Weeks 2, 4, 8, 12 and 16
Reported as:
Count of participants · Participants
Number of Subjects With Abnormal Not Clinically Significant ECG Findings at Each Visit
ParticipantsPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline9762118
Week 211851824
Week 413862317
Week 8151052119
Week 1214851914
Week 1616422017
SecondaryNumber of Subjects With Abnormal Clinically Significant ECG Findings at Each Visit

All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reported results are cardiovascular system-examination findings. Abnormal clinically significant ECG findings were decided by investigator. The findings are presented as Abnormal clinically significant ECG.

Time frame:
At Weeks 2, 4, 8, 12 and 16
Reported as:
Count of participants · Participants
Number of Subjects With Abnormal Clinically Significant ECG Findings at Each Visit
ParticipantsPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline00000
Week 200000
Week 400100
Week 800010
Week 1200000
Week 1600000
SecondaryChange From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (RR)

All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record. In categories the number of subjects analyzed (N) for each week is mentioned for each reporting group respectively.

Time frame:
At Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · mSec
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (RR)
mSecPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline913.5 ± 128.5891.4 ± 145.6934.3 ± 120.3927.8 ± 135.5935.9 ± 151.2
Week 2: Change from baseline17.3 ± 84.223.0 ± 101.7-12.6 ± 99.727.3 ± 94.7-2.6 ± 137.7
Week 4: Change from baseline1.6 ± 82.824.8 ± 101.920.5 ± 108.527.3 ± 92.64.5 ± 108.0
Week 8: Change from baseline )35.8 ± 108.724.8 ± 104.619.0 ± 128.622.3 ± 109.2-22.6 ± 90.1
Week 12: Change from baseline25.5 ± 143.418.0 ± 110.9-23.3 ± 105.127.2 ± 95.9-1.4 ± 107.9
Week 16: Change from baseline-22.4 ± 135.52.4 ± 138.5-25.4 ± 149.65.9 ± 110.8-8.0 ± 110.3
SecondaryChange From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (PR)

All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record.

Time frame:
At Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · mSec
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (PR)
mSecPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline162.6 ± 21.8167.8 ± 16.5162.9 ± 21.7157.2 ± 21.7164.2 ± 25.8
Week 2: Change from baseline1.2 ± 9.74.6 ± 11.75.2 ± 11.83.0 ± 10.2-2.2 ± 16.3
Week 4: Change from baseline0.0 ± 11.25.9 ± 12.32.9 ± 12.13.8 ± 17.71.8 ± 13.8
Week 8: Change from baseline1.5 ± 15.13.6 ± 10.4-0.1 ± 12.34.3 ± 10.3-1.1 ± 14.5
Week 12: Change from baseline1.6 ± 11.53.9 ± 11.70.7 ± 16.21.9 ± 11.4-1.5 ± 16.9
Week 16: Change from baseline0.4 ± 11.32.2 ± 13.32.4 ± 16.02.8 ± 11.1-0.4 ± 13.3
SecondaryChange From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (QT)

All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record.

Time frame:
At Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · mSec
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (QT)
mSecPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline394.5 ± 31.2397.2 ± 28.7403.5 ± 26.9402.3 ± 40.3401.2 ± 28.0
Week 2: Change from baseline3.6 ± 18.00.2 ± 17.81.1 ± 21.7-0.9 ± 35.6-3.2 ± 25.2
Week 4: Change from baseline4.7 ± 18.5-0.1 ± 18.54.8 ± 35.20.2 ± 28.10.8 ± 21.5
Week 8: Change from baseline2.0 ± 19.01.5 ± 17.26.5 ± 28.40.5 ± 34.6-4.0 ± 20.3
Week 12: Change from baseline1.4 ± 25.10.8 ± 21.6-8.9 ± 20.6-1.1 ± 32.91.0 ± 19.5
Week 16: Change from baseline-1.7 ± 23.3-4.7 ± 24.4-3.2 ± 27.6-4.1 ± 38.1-2.4 ± 25.5
SecondaryChange From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (QTc)

All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record. QTc: QT corrected interval.

Time frame:
At Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · mSec
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (QTc)
mSecPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline410.6 ± 20.9417.9 ± 21.4416.4 ± 14.1415.9 ± 29.3415.2 ± 22.1
Week 2: Change from baseline1.6 ± 14.3-2.4 ± 11.22.9 ± 14.7-4.9 ± 28.2-2.1 ± 15.4
Week 4: Change from baseline5.6 ± 16.1-5.4 ± 11.81.7 ± 19.9-2.9 ± 24.50.2 ± 16.3
Week 8: Change from baseline-3.9 ± 18.5-3.8 ± 12.32.3 ± 10.8-2.2 ± 27.51.2 ± 14.7
Week 12: Change from baseline-2.4 ± 20.8-3.2 ± 14.9-3.1 ± 14.4-4.7 ± 31.30.5 ± 14.4
Week 16: Change from baseline2.8 ± 14.9-4.8 ± 13.64.3 ± 17.5-4.5 ± 31.2-1.6 ± 13.6
SecondaryChange From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (QTcF)

All ECGs were performed after the subject had rested for 5 minutes in a semi-recumbent position. The same model of ECG recorder was used throughout the study for any given subject wherever possible. All ECG reports were reviewed, signed and dated by the Investigator or delegated physician. Reports were then filed with the subject's medical record. QTcF: QT interval with Fridericia's correction.

Time frame:
At Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · mSec
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in ECG Intervals (QTcF)
mSecPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline407.2 ± 20.6413.8 ± 19.9413.2 ± 14.3413.1 ± 30.7411.4 ± 18.6
Week 2: Change from baseline1.2 ± 13.7-3.5 ± 10.23.4 ± 13.4-4.8 ± 29.5-2.5 ± 15.7
Week 4: Change from baseline4.8 ± 16.4-4.2 ± 11.52.1 ± 23.4-3.5 ± 24.70.4 ± 15.4
Week 8: Change from baseline-2.8 ± 15.9-2.7 ± 10.94.0 ± 13.2-2.6 ± 28.7-0.4 ± 16.1
Week 12: Change from baseline-1.7 ± 18.5-1.9 ± 13.9-5.1 ± 13.2-5.1 ± 30.81.1 ± 14.6
Week 16: Change from baseline2.6 ± 15.1-5.6 ± 14.21.5 ± 14.5-4.8 ± 32.7-1.3 ± 16.4
SecondaryNumber of Subjects With Absolute QTcF Values by Category at Each Visit: ≤450, >450 to ≤480, >480 to ≤500, >500 Msec

Absolute QTcF values reported.

Time frame:
From baseline to Weeks 2, 4, 8, 12 and 16
Reported as:
Count of participants · Participants
Number of Subjects With Absolute QTcF Values by Category at Each Visit: ≤450, >450 to ≤480, >480 to ≤500, >500 Msec
ParticipantsPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline: missing00000
Baseline: <=450 msec4630165150
Baseline: >450 to <=480 msec11102
Baseline: >480 to <=500 msec00000
Baseline: >500 msec00010
Week 2: missing30001
Week 2: <=450 msec4430165250
Week 2: >450 to <=480 msec01101
Week 2: >480 to <=500 msec00000
Week 2: >500 msec00000
Week 4: missing20014
Week 4: <=450 msec4430165147
Week 4: >450 to <=480 msec11001
Week 4: >480 to <=500 msec00000
Week 4: >500 msec00100
Week 8: missing30006
Week 8: <=450 msec4430175246
Week 8: >450 to <=480 msec01000
Week 8: >480 to <=500 msec00000
Week 8: >500 msec00000
Week 12: missing31127
Week 12: <=450 msec4430165045
Week 12: >450 to <=480 msec00000
Week 12: >480 to <=500 msec00000
Week 12: >500 msec00000
Week 16: missing41117
Week 16: <=450 msec4230155144
Week 16: >450 to <=480 msec10101
Week 16: >480 to <=500 msec00000
Week 16: >500 msec00000
SecondaryNumber of Subjects With Change From Baseline in ECG QTcF Values by Category at Weeks 2, 4, 8, 12 and 16: ≤0, >0 to ≤30, >30 to ≤60, >60 Msec

Increase from Baseline overtime was reported.

Time frame:
From baseline to Weeks 2, 4, 8, 12 and 16
Reported as:
Count of participants · Participants
Number of Subjects With Change From Baseline in ECG QTcF Values by Category at Weeks 2, 4, 8, 12 and 16: ≤0, >0 to ≤30, >30 to ≤60, >60 Msec
ParticipantsPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Week 2: missing30001
Week 2: <=0 msec192182729
Week 2: >0 to <=30 msec251082422
Week 2: >30 to <=60 msec00110
Week 2: >60 msec00000
Week 4: missing20014
Week 4: <=0 msec202082724
Week 4: >0 to <=30 msec231182422
Week 4: >30 to <=60 msec20002
Week 4: >60 msec00100
Week 8: missing30006
Week 8: <=0 msec242082519
Week 8: >0 to <=30 msec201192626
Week 8: >30 to <=60 msec00011
Week 8: >60 msec00000
Week 12: missing31127
Week 12: <=0 msec2415102922
Week 12: >0 to <=30 msec191562122
Week 12: >30 to <=60 msec10001
Week 12: >60 msec00000
Week 16: missing41117
Week 16: <=0 msec181872624
Week 16: >0 to <=30 msec231292420
Week 16: >30 to <=60 msec20011
Week 16: >60 msec00000
SecondaryChange From Baseline in the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS) at Weeks 4, 12 and 16

The Columbia Suicide Severity Rating Scale (C-SSRS) is a rating scale created to evaluate suicidality in adults and children over the age of 12. It rates an individual's degree of suicidal ideation on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The version used was the eC-SSRS, which is a subject-reported version of the scale. Shifts from baseline versus post-baseline to demonstrate changes in categories (cat) were reported using cat 1 (No Suicidal Ideation or Behaviour), cat 2 (Suicidal Ideation) and cat 3 (Suicidal Behaviour).

Time frame:
Baseline to Weeks 4, 12 and 16
Reported as:
Count of participants · Participants
Change From Baseline in the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS) at Weeks 4, 12 and 16
ParticipantsPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Week 4: shift from cat 1 to cat 13414133838
Week 4: shift from cat 1 to cat 210000
Week 4: shift from cat 1 to cat 300000
Week 4: shift from cat 2 to cat 157247
Week 4: shift from cat 2 to cat 210000
Week 4: shift from cat 2 to cat 300000
Week 4: shift from cat 3 to cat 115121
Week 4: shift from cat 3 to cat 200000
Week 4: shift from cat 3 to cat 300000
Week 12: shift from cat 1 to cat 13414124033
Week 12: shift from cat 1 to cat 200000
Week 12: shift from cat 1 to cat 300000
Week 12: shift from cat 2 to cat 175327
Week 12: shift from cat 2 to cat 202010
Week 12: shift from cat 2 to cat 300000
Week 12: shift from cat 3 to cat 115121
Week 12: shift from cat 3 to cat 200000
Week 12: shift from cat 3 to cat 300000
Week 16: shift from cat 1 to cat 13315124033
Week 16: shift from cat 1 to cat 200000
Week 16: shift from cat 1 to cat 300000
Week 16: shift from cat 2 to cat 166347
Week 16: shift from cat 2 to cat 211000
Week 16: shift from cat 2 to cat 300000
Week 16: shift from cat 3 to cat 115121
Week 16: shift from cat 3 to cat 200000
Week 16: shift from cat 3 to cat 300000
SecondaryChange From Baseline at Weeks 2, 4, 12 and 16 for Clinical Laboratory Parameters Hematology: Erythrocytes

Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.

Time frame:
From baseline to Weeks 2, 4, 12 and 16
Reported as:
Mean · 10^12*cells/L
Change From Baseline at Weeks 2, 4, 12 and 16 for Clinical Laboratory Parameters Hematology: Erythrocytes
10^12*cells/LPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline4.568 ± 0.3924.537 ± 0.3754.510 ± 0.3654.516 ± 0.4294.563 ± 0.406
Week 2: Change from baseline-0.106 ± 0.262-0.108 ± 0.2180.007 ± 0.254-0.095 ± 0.215-0.090 ± 0.210
Week 4: Change from baseline-0.094 ± 0.278-0.083 ± 0.2170.072 ± 0.200-0.087 ± 0.203-0.077 ± 0.229
Week 12: Change from baseline-0.057 ± 0.277-0.085 ± 0.2560.039 ± 0.273-0.057 ± 0.265-0.057 ± 0.202
Week 16: Change from baseline-0.060 ± 0.293-0.023 ± 0.250-0.033 ± 0.290-0.085 ± 0.254-0.040 ± 0.240
SecondaryChange From Baseline at Weeks 2, 4, 12 and 16 for Clinical Laboratory Parameters Hematology: Hematocrit

Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.

Time frame:
From baseline to Weeks 2, 4, 12 and 16
Reported as:
Mean · Volume proportion
Change From Baseline at Weeks 2, 4, 12 and 16 for Clinical Laboratory Parameters Hematology: Hematocrit
Volume proportionPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline0.4230 ± 0.03470.4184 ± 0.03030.4102 ± 0.03840.4088 ± 0.03120.4182 ± 0.0346
Week 2: Change from baseline-0.0121 ± 0.0261-0.0079 ± 0.02200.0016 ± 0.0211-0.0079 ± 0.0195-0.0138 ± 0.0199
Week 4: Change from baseline-0.0097 ± 0.0249-0.0060 ± 0.01940.0075 ± 0.0144-0.0080 ± 0.0186-0.0100 ± 0.0234
Week 12: Change from baseline-0.0106 ± 0.0294-0.0036 ± 0.02200.0087 ± 0.0276-0.0083 ± 0.0258-0.0115 ± 0.0231
Week 16: Change from baseline-0.0140 ± 0.0258-0.0006 ± 0.02500.0015 ± 0.0244-0.0100 ± 0.0235-0.0099 ± 0.0274
SecondaryChange From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Hematology: Hemoglobin

Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.

Time frame:
From baseline to Weeks 2, 4, 12 and 16
Reported as:
Mean · g/L
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Hematology: Hemoglobin
g/LPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline138.4 ± 10.9137.3 ± 10.0136.4 ± 11.6134.6 ± 9.8135.6 ± 11.4
Week 2: Change from baseline-3.0 ± 7.8-3.0 ± 6.6-0.2 ± 7.5-2.8 ± 6.3-2.5 ± 5.4
Week 4: Change from baseline-2.7 ± 8.1-2.6 ± 6.72.6 ± 5.3-2.8 ± 5.7-2.4 ± 6.2
Week 12: Change from baseline-2.1 ± 7.7-2.5 ± 7.50.8 ± 7.5-2.3 ± 7.1-1.5 ± 5.9
Week 16: Change from baseline-1.9 ± 8.5-0.7 ± 6.9-1.7 ± 8.2-2.6 ± 6.9-1.1 ± 6.4
SecondaryChange From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Hematology: Erythrocytes Mean Corpuscular Volume

Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.

Time frame:
From baseline to Weeks 2, 4, 12 and 16
Reported as:
Mean · fL
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Hematology: Erythrocytes Mean Corpuscular Volume
fLPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline92.74 ± 4.6592.39 ± 4.5190.92 ± 3.0090.82 ± 5.2591.88 ± 5.69
Week 2: Change from baseline-0.56 ± 2.350.51 ± 2.580.24 ± 2.020.10 ± 1.72-1.29 ± 3.35
Week 4: Change from baseline-0.22 ± 2.530.49 ± 2.310.27 ± 2.85-0.10 ± 1.92-0.73 ± 4.48
Week 12: Change from baseline-1.22 ± 3.300.98 ± 3.411.18 ± 2.72-0.77 ± 2.66-1.47 ± 4.49
Week 16: Change from baseline-1.91 ± 2.990.36 ± 3.411.05 ± 2.39-0.55 ± 4.13-1.42 ± 5.06
SecondaryChange From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Hematology: Leukocytes, Platelets, Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils

Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.

Time frame:
From baseline to Weeks 2, 4, 12 and 16
Reported as:
Mean · 10^9*cells/L
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Hematology: Leukocytes, Platelets, Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils
10^9*cells/LPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline (Leukocytes)6.09 ± 1.806.17 ± 1.896.32 ± 1.356.31 ± 1.746.40 ± 1.76
Week 2: Change from baseline (Leukocytes)-0.19 ± 1.02-0.24 ± 0.99-0.13 ± 0.97-0.25 ± 1.33-0.12 ± 1.44
Week 4: Change from baseline (Leukocytes)0.41 ± 2.80-0.09 ± 0.960.16 ± 1.02-0.27 ± 1.44-0.20 ± 1.04
Week 12: Change from baseline (Leukocytes)-0.12 ± 1.28-0.11 ± 1.070.08 ± 1.98-0.29 ± 1.55-0.08 ± 1.59
Week 16: Change from baseline (Leukocytes)-0.20 ± 1.150.19 ± 1.84-0.05 ± 1.20-0.12 ± 1.880.09 ± 1.18
Baseline (Platelets)273.6 ± 53.7270.8 ± 66.2254.9 ± 37.2280.6 ± 62.8277.0 ± 59.3
Week 2: Change from baseline (Platelets)0.6 ± 36.2-3.9 ± 31.8-6.0 ± 22.4-5.5 ± 32.4-3.0 ± 30.7
Week 4: Change from baseline (Platelets)9.5 ± 43.7-2.1 ± 27.67.6 ± 35.8-5.7 ± 29.9-1.4 ± 34.4
Week 12: Change from baseline (Platelets)8.2 ± 54.7-0.5 ± 33.114.7 ± 23.90.0 ± 30.61.3 ± 45.7
Week16: Change from baseline (Platelets)12.4 ± 28.65.7 ± 37.33.9 ± 28.71.2 ± 32.99.5 ± 38.0
Baseline (Basophils)0.03 ± 0.040.05 ± 0.050.04 ± 0.050.03 ± 0.050.03 ± 0.04
Week 2: Change from baseline (Basophils)0.00 ± 0.040.00 ± 0.02-0.02 ± 0.040.00 ± 0.040.01 ± 0.04
Week 4: Change from baseline (Basophils)0.00 ± 0.05-0.01 ± 0.03-0.02 ± 0.04-0.01 ± 0.040.01 ± 0.05
Week 12: Change from baseline (Basophils)0.00 ± 0.04-0.01 ± 0.04-0.02 ± 0.060.00 ± 0.050.00 ± 0.03
Week 16: Change from baseline (Basophils)0.00 ± 0.040.00 ± 0.000.00 ± 0.05-0.01 ± 0.040.01 ± 0.05
Baseline (Eosinophils)0.14 ± 0.090.19 ± 0.120.18 ± 0.150.20 ± 0.240.18 ± 0.14
Week 2: Change from baseline (Eosinophils)0.00 ± 0.060.00 ± 0.09-0.01 ± 0.07-0.03 ± 0.12-0.02 ± 0.09
Week 4: Change from baseline (Eosinophils)-0.01 ± 0.09-0.01 ± 0.08-0.01 ± 0.11-0.03 ± 0.16-0.02 ± 0.07
Week 12: Change from baseline (Eosinophils)0.02 ± 0.090.02 ± 0.090.00 ± 0.11-0.05 ± 0.19-0.03 ± 0.09
Week 16: Change from baseline (Eosinophils)0.00 ± 0.10-0.02 ± 0.08-0.01 ± 0.13-0.05 ± 0.17-0.02 ± 0.11
Baseline (Lymphocytes)1.98 ± 0.671.90 ± 0.631.78 ± 0.502.11 ± 0.662.00 ± 0.62
Week 2: Change from baseline (Lymphocytes)-0.06 ± 0.34-0.11 ± 0.33-0.10 ± 0.31-0.11 ± 0.41-0.14 ± 0.39
Week 4: Change from baseline (Lymphocytes)-0.08 ± 0.38-0.13 ± 0.340.04 ± 0.45-0.08 ± 0.50-0.02 ± 0.38
Week 12: Change from baseline (Lymphocytes)-0.05 ± 0.36-0.08 ± 0.34-0.07 ± 0.24-0.09 ± 0.47-0.05 ± 0.29
Week 16: Change from baseline (Lymphocytes)-0.14 ± 0.46-0.11 ± 0.40-0.07 ± 0.32-0.13 ± 0.390.01 ± 0.36
Baseline (Monocytes)0.44 ± 0.130.47 ± 0.140.51 ± 0.100.47 ± 0.140.46 ± 0.17
Week 2: Change from baseline (Monocytes)0.00 ± 0.09-0.02 ± 0.13-0.02 ± 0.13-0.05 ± 0.14-0.01 ± 0.11
Week 4: Change from baseline (Monocytes)0.02 ± 0.09-0.03 ± 0.100.01 ± 0.12-0.03 ± 0.11-0.02 ± 0.12
Week 12: Change from baseline (Monocytes)0.01 ± 0.11-0.03 ± 0.10-0.06 ± 0.11-0.03 ± 0.130.00 ± 0.15
Week 16: Change from baseline (Monocytes)0.01 ± 0.11-0.02 ± 0.14-0.03 ± 0.130.00 ± 0.130.00 ± 0.14
Baseline (Neutrophils)3.50 ± 1.343.59 ± 1.333.81 ± 1.133.51 ± 1.413.73 ± 1.28
Week 2: Change from baseline (Neutrophils)-0.14 ± 0.79-0.15 ± 0.840.03 ± 0.80-0.08 ± 1.240.01 ± 1.32
Week 4: Change from baseline (Neutrophils)0.11 ± 1.040.09 ± 0.860.14 ± 0.70-0.13 ± 1.24-0.16 ± 0.91
Week 12: Change from baseline (Neutrophils)-0.11 ± 1.16-0.02 ± 0.970.22 ± 1.79-0.13 ± 1.26-0.01 ± 1.39
Week 16: Change from baseline (Neutrophils)-0.08 ± 1.190.33 ± 1.700.05 ± 0.960.04 ± 1.730.10 ± 0.95
SecondaryChange From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Hematology: Leukocytes, Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils

Blood samples for clinical hematology assessment were collected and sent to the central laboratory for analysis.

Time frame:
From baseline to Weeks 2, 4, 12 and 16
Reported as:
Mean · Percentage of total white blood cells
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Hematology: Leukocytes, Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils
Percentage of total white blood cellsPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline (Basophils/ Leukocytes)0.61 ± 0.360.72 ± 0.340.59 ± 0.260.69 ± 0.470.59 ± 0.31
Week 2: Change from baseline (Basophils/ Leukocytes)0.02 ± 0.22-0.01 ± 0.19-0.01 ± 0.18-0.04 ± 0.300.07 ± 0.20
Week 4: Change from baseline (Basophils/ Leukocytes)0.03 ± 0.28-0.04 ± 0.21-0.02 ± 0.22-0.06 ± 0.310.08 ± 0.30
Week 12: Change from baseline (Basophils/ Leukocytes)0.02 ± 0.350.01 ± 0.260.03 ± 0.15-0.07 ± 0.310.05 ± 0.21
Week 16: Change from baseline (Basophils/ Leukocytes)0.00 ± 0.270.05 ± 0.200.06 ± 0.22-0.05 ± 0.320.01 ± 0.19
Baseline (Eosinophils/ Leukocytes)2.17 ± 1.222.89 ± 1.672.66 ± 1.802.97 ± 3.432.76 ± 1.78
Week 2: Change from baseline (Eosinophils/ Leukocytes)0.16 ± 0.870.20 ± 1.01-0.12 ± 0.75-0.24 ± 1.78-0.13 ± 1.17
Week 4: Change from baseline (Eosinophils/ Leukocytes)-0.13 ± 0.84-0.06 ± 0.99-0.15 ± 1.14-0.43 ± 2.43-0.17 ± 0.99
Week 12: Change from baseline (Eosinophils/ Leukocytes)0.33 ± 1.220.41 ± 1.490.11 ± 1.16-0.53 ± 2.58-0.27 ± 1.43
Week16: Change from baseline (Eosinophils/ Leukocytes)0.10 ± 1.59-0.15 ± 1.180.00 ± 1.53-0.42 ± 2.33-0.32 ± 1.57
Baseline (Lymphocytes/ Leukocytes)32.87 ± 7.0231.31 ± 6.3128.71 ± 7.0734.20 ± 9.4231.95 ± 7.49
Week 2: Change from baseline (Lymphocytes/ Leukocytes)0.27 ± 5.12-0.54 ± 5.60-1.32 ± 4.45-0.83 ± 7.48-1.37 ± 6.02
Week 4: Change from baseline (Lymphocytes/ Leukocytes)-1.24 ± 5.98-1.25 ± 5.12-0.89 ± 3.68-0.43 ± 7.030.68 ± 4.85
Week 12: Change from baseline (Lymphocytes/ Leukocytes)-0.32 ± 6.82-0.51 ± 6.590.13 ± 4.78-0.41 ± 6.56-0.07 ± 4.94
Week 16: Change from baseline (Lymphocytes/ Leukocytes)-0.89 ± 7.90-1.40 ± 8.07-0.75 ± 4.70-0.95 ± 7.10-0.70 ± 4.39
Baseline (Monocytes/Leukocytes)7.41 ± 1.767.71 ± 2.078.18 ± 1.627.55 ± 1.677.15 ± 1.67
Week 2: Change from baseline (Monocytes/Leukocytes)0.19 ± 1.110.05 ± 1.83-0.24 ± 2.01-0.36 ± 1.590.08 ± 1.20
Week 4: Change from baseline (Monocytes/Leukocytes)0.24 ± 1.31-0.19 ± 1.24-0.29 ± 1.71-0.13 ± 1.250.21 ± 1.81
Week 12: Change from baseline (Monocytes/Leukocytes)0.45 ± 1.34-0.19 ± 1.64-0.67 ± 1.27-0.01 ± 1.570.24 ± 1.52
Week 16: Change from baseline (Monocytes/Leukocytes)0.48 ± 1.67-0.50 ± 1.75-0.48 ± 1.450.27 ± 1.670.08 ± 1.68
Baseline (Neutrophils/Leukocytes)56.93 ± 8.1257.37 ± 7.1359.85 ± 8.0754.59 ± 0.4357.56 ± 8.01
Week 2: Change from baseline (Neutrophils/Leukocytes)-0.64 ± 6.110.29 ± 6.641.70 ± 5.111.47 ± 8.321.36 ± 6.75
Week 4: Change from baseline (Neutrophils/Leukocytes)1.10 ± 6.921.54 ± 5.781.35 ± 4.761.05 ± 8.38-0.80 ± 6.01
Week 12: Change from baseline (Neutrophils/Leukocytes)-0.48 ± 7.920.27 ± 7.610.40 ± 5.401.01 ± 7.540.05 ± 5.60
Week 16: Change from baseline (Neutrophils/Leukocytes)0.30 ± 9.572.00 ± 9.271.17 ± 5.311.14 ± 8.140.94 ± 5.30
SecondaryChange From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Sodium, Potassium, Glucose, Urea Nitrogen, Calcium, Phosphate, Bicarbonate, Magnesium and Chloride

Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.

Time frame:
From baseline to Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · mmol/L
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Sodium, Potassium, Glucose, Urea Nitrogen, Calcium, Phosphate, Bicarbonate, Magnesium and Chloride
mmol/LPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline (Sodium)141.3 ± 2.0141.6 ± 2.4141.6 ± 2.9141.2 ± 1.8141.3 ± 2.0
Week 2: Change from baseline (Sodium)-0.1 ± 1.90.1 ± 2.1-0.6 ± 2.0-0.5 ± 1.8-0.5 ± 1.7
Week 4: Change from baseline (Sodium)-0.5 ± 1.7-0.2 ± 2.1-0.9 ± 2.4-0.3 ± 1.80.0 ± 1.6
Week 8: Change from baseline (Sodium)0.0 ± 1.8-0.8 ± 2.5-0.6 ± 1.60.1 ± 2.00.1 ± 1.7
Week 12: Change from baseline (Sodium)-0.5 ± 1.9-0.6 ± 2.5-0.9 ± 1.70.0 ± 2.2-0.1 ± 1.8
Week 16: Change from baseline (Sodium)-0.2 ± 1.7-0.1 ± 2.1-0.1 ± 2.0-0.2 ± 2.0-0.3 ± 1.8
Baseline (Potassium)4.51 ± 0.384.43 ± 0.304.23 ± 0.334.37 ± 0.444.36 ± 0.45
Week 2: Change from baseline (Potassium)-0.02 ± 0.35-0.08 ± 0.360.06 ± 0.350.01 ± 0.44-0.07 ± 0.40
Week 4: Change from baseline (Potassium)-0.04 ± 0.39-0.09 ± 0.400.06 ± 0.27-0.02 ± 0.45-0.13 ± 0.31
Week 8: Change from baseline (Potassium)0.06 ± 0.39-0.10 ± 0.34-0.05 ± 0.300.02 ± 0.51-0.11 ± 0.42
Week 12: Change from baseline (Potassium)-0.10 ± 0.40-0.07 ± 0.340.10 ± 0.410.03 ± 0.51-0.16 ± 0.40
Week 16: Change from baseline (Potassium)-0.13 ± 0.39-0.10 ± 0.33-0.04 ± 0.330.04 ± 0.45-0.16 ± 0.40
Baseline (Glucose)5.06 ± 0.835.32 ± 1.115.16 ± 0.715.04 ± 0.745.81 ± 2.70
Week 2: Change from baseline (Glucose)0.22 ± 1.12-0.07 ± 0.920.04 ± 1.010.28 ± 0.970.21 ± 1.89
Week 4: Change from baseline (Glucose)0.24 ± 0.730.02 ± 0.87-0.24 ± 1.080.02 ± 0.87-0.29 ± 2.39
Week 8: Change from baseline (Glucose)0.12 ± 0.54-0.15 ± 1.15-0.13 ± 1.170.01 ± 1.09-0.12 ± 1.35
Week 12: Change from baseline (Glucose)-0.06 ± 0.94-0.09 ± 1.060.13 ± 0.550.21 ± 1.48-0.34 ± 1.82
Week 16: Change from baseline (Glucose)0.14 ± 0.810.06 ± 1.030.10 ± 0.940.09 ± 1.02-0.43 ± 1.58
Baseline (Urea Nitrogen)5.74 ± 1.495.64 ± 1.545.70 ± 1.455.34 ± 1.515.31 ± 1.26
Week 2: Change from baseline (Urea Nitrogen)-0.43 ± 1.050.04 ± 1.210.50 ± 1.350.50 ± 1.250.24 ± 1.15
Week 4: Change from baseline (Urea Nitrogen)-0.30 ± 1.580.12 ± 0.950.17 ± 1.250.36 ± 1.420.12 ± 1.22
Week 8: Change from baseline (Urea Nitrogen)-0.23 ± 1.10-0.34 ± 1.180.13 ± 1.710.53 ± 1.58-0.03 ± 1.34
Week 12: Change from baseline (Urea Nitrogen)-0.21 ± 1.20-0.17 ± 1.130.45 ± 2.110.31 ± 1.09-0.10 ± 1.31
Week 16: Change from baseline (Urea Nitrogen)-0.24 ± 1.41-0.19 ± 1.32-0.03 ± 1.570.24 ± 1.11-0.01 ± 1.25
Baseline (Calcium)2.348 ± 0.0822.354 ± 0.0932.325 ± 0.0912.347 ± 0.1172.342 ± 0.091
Week 2: Change from baseline (Calcium)-0.046 ± 0.081-0.052 ± 0.0820.011 ± 0.102-0.019 ± 0.079-0.050 ± 0.101
Week 4: Change from baseline (Calcium)-0.035 ± 0.094-0.035 ± 0.0770.028 ± 0.068-0.018 ± 0.099-0.036 ± 0.094
Week 8: Change from baseline (Calcium)-0.008 ± 0.109-0.034 ± 0.0850.002 ± 0.091-0.021 ± 0.108-0.042 ± 0.077
Week 12: Change from baseline (Calcium)-0.006 ± 0.088-0.018 ± 0.0910.014 ± 0.108-0.014 ± 0.097-0.042 ± 0.084
Week 16 Change from baseline (Calcium)-0.005 ± 0.090-0.033 ± 0.0930.003 ± 0.097-0.009 ± 0.100-0.027 ± 0.104
Baseline (Phosphate)1.28 ± 0.151.28 ± 0.151.17 ± 0.151.26 ± 0.161.22 ± 0.15
Week 2: Change from baseline (Phosphate)-0.02 ± 0.130.00 ± 0.130.03 ± 0.150.00 ± 0.15-0.02 ± 0.17
Week 4: Change from baseline (Phosphate)0.00 ± 0.140.00 ± 0.160.05 ± 0.09-0.01 ± 0.15-0.03 ± 0.15
Week 8: Change from baseline (Phosphate)-0.01 ± 0.13-0.02 ± 0.150.07 ± 0.110.02 ± 0.18-0.02 ± 0.14
Week 12: Change from baseline (Phosphate)-0.02 ± 0.16-0.02 ± 0.170.06 ± 0.150.02 ± 0.19-0.06 ± 0.14
Week 16: Change from baseline (Phosphate)-0.02 ± 0.17-0.01 ± 0.160.00 ± 0.14-0.01 ± 0.17-0.01 ± 0.13
Baseline (Bicarbonate)25.5 ± 2.426.6 ± 3.426.2 ± 3.726.7 ± 2.726.0 ± 2.9
Week 2: Change from baseline (Bicarbonate)0.3 ± 1.70.0 ± 2.0-0.6 ± 2.3-0.5 ± 2.1-0.2 ± 2.0
Week 4: Change from baseline (Bicarbonate)0.2 ± 2.0-0.1 ± 2.0-0.1 ± 2.3-0.4 ± 2.10.0 ± 1.7
Week 8: Change from baseline (Bicarbonate)0.3 ± 1.80.0 ± 2.3-0.2 ± 2.1-0.6 ± 1.90.3 ± 1.9
Week 12: Change from baseline (Bicarbonate)0.6 ± 2.1-0.4 ± 2.1-0.5 ± 2.4-0.6 ± 1.9-0.2 ± 1.9
Week 16: Change from baseline (Bicarbonate)0.4 ± 1.5-0.1 ± 2.3-0.5 ± 2.7-0.3 ± 2.3-0.1 ± 2.1
Baseline (Magnesium)0.809 ± 0.0750.833 ± 0.0840.826 ± 0.0750.821 ± 0.0670.817 ± 0.076
Week 2: Change from baseline (Magnesium)-0.011 ± 0.066-0.027 ± 0.070-0.009 ± 0.065-0.013 ± 0.066-0.037 ± 0.057
Week 4: Change from baseline (Magnesium)-0.008 ± 0.054-0.035 ± 0.0570.002 ± 0.052-0.017 ± 0.061-0.017 ± 0.060
Week 8: Change from baseline (Magnesium)0.005 ± 0.056-0.016 ± 0.0650.010 ± 0.0480.005 ± 0.077-0.008 ± 0.063
Week 12: Change from baseline (Magnesium)-0.033 ± 0.059-0.025 ± 0.060-0.035 ± 0.058-0.012 ± 0.070-0.016 ± 0.059
Week 16: Change from baseline (Magnesium)-0.024 ± 0.052-0.043 ± 0.069-0.022 ± 0.063-0.025 ± 0.057-0.022 ± 0.052
Baseline (Chloride)105.6 ± 2.2105.4 ± 2.1105.5 ± 2.4104.8 ± 2.4105.3 ± 2.6
Week 2: Change from baseline (Chloride)0.2 ± 2.00.3 ± 2.20.3 ± 2.20.5 ± 2.2-0.1 ± 1.9
Week 4: Change from baseline (Chloride)-0.3 ± 1.7-0.2 ± 1.8-0.7 ± 2.50.3 ± 2.20.2 ± 2.1
Week 8: Change from baseline (Chloride)0.2 ± 1.9-0.3 ± 2.0-0.4 ± 1.80.5 ± 2.30.3 ± 1.6
Week 12: Change from baseline (Chloride)-0.5 ± 2.2-0.1 ± 2.2-0.3 ± 1.90.5 ± 2.30.8 ± 2.0
Week 16: Change from baseline (Chloride)-0.5 ± 1.80.2 ± 2.20.6 ± 2.60.1 ± 1.90.1 ± 2.2
SecondaryChange From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Creatinine and Bilirubin

Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.

Time frame:
From baseline to Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · umol/L
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Creatinine and Bilirubin
umol/LPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline (Creatinine)68.8 ± 11.268.5 ± 11.768.1 ± 14.971.4 ± 11.370.1 ± 11.9
Week 2: Change from baseline (Creatinine)0.8 ± 7.2-0.2 ± 8.92.9 ± 9.70.7 ± 6.50.6 ± 7.0
Week 4: Change from baseline (Creatinine)-0.9 ± 6.00.6 ± 8.12.7 ± 9.81.9 ± 7.80.2 ± 7.8
Week 8: Change from baseline (Creatinine)1.0 ± 6.3-1.0 ± 7.84.8 ± 5.30.6 ± 7.80.5 ± 9.0
Week 12: Change from baseline (Creatinine)0.7 ± 8.92.1 ± 7.74.2 ± 11.2-0.5 ± 7.4-2.8 ± 8.0
Week 16: Change from baseline (Creatinine)0.1 ± 7.61.5 ± 6.96.5 ± 8.5-0.9 ± 8.2-0.2 ± 12.9
Baseline (Bilirubin)9.1 ± 4.18.4 ± 2.98.9 ± 3.19.6 ± 5.08.1 ± 2.8
Week 2: Change from baseline (Bilirubin)-0.5 ± 2.20.1 ± 2.21.4 ± 2.01.1 ± 3.31.7 ± 2.5
Week 4: Change from baseline (Bilirubin)-0.2 ± 2.60.4 ± 2.72.3 ± 2.81.0 ± 3.31.3 ± 3.0
Week 8: Change from baseline (Bilirubin)-0.1 ± 2.80.1 ± 2.11.8 ± 2.10.3 ± 3.10.9 ± 2.6
Week 12: Change from baseline (Bilirubin)-0.1 ± 2.40.7 ± 2.40.8 ± 2.7-0.2 ± 3.81.0 ± 2.7
Week 16: Change from baseline (Bilirubin)0.2 ± 2.4-0.3 ± 3.40.8 ± 2.8-0.8 ± 3.7-0.4 ± 2.5
SecondaryChange From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Creatinine Kinase, Alkaline Phosphatase, Aspartate Aminotransferase, Alanine Aminotransferase and Gamma Glutamyl Transferase

Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.

Time frame:
From baseline to Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · U/L
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Creatinine Kinase, Alkaline Phosphatase, Aspartate Aminotransferase, Alanine Aminotransferase and Gamma Glutamyl Transferase
U/LPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline (Creatine Kinase)102.5 ± 117.291.6 ± 55.6104.2 ± 62.0161.8 ± 291.4139.8 ± 159.3
Week 2: Change from baseline (Creatine Kinase)28.2 ± 161.87.1 ± 45.58.7 ± 59.6-39.2 ± 280.5-44.3 ± 154.1
Week 4: Change from baseline (Creatine Kinase)-1.3 ± 36.82.7 ± 23.44.3 ± 44.2-30.2 ± 293.1-40.1 ± 163.0
Week 8: Change from baseline (Creatine Kinase)15.5 ± 106.630.6 ± 127.3158.1 ± 580.1-36.9 ± 275.84.0 ± 76.1
Week 12: Change from baseline (Creatine Kinase)7.2 ± 49.716.1 ± 44.711.7 ± 116.5-13.3 ± 77.4-40.3 ± 174.5
Week 16: Change from baseline (Creatine Kinase)7.3 ± 37.33.2 ± 34.35.6 ± 54.8-48.8 ± 267.0-44.1 ± 172.2
Baseline (Alkaline Phosphatase)79.8 ± 24.185.9 ± 18.480.6 ± 19.491.3 ± 43.486.1 ± 25.5
Week 2: Change from baseline (Alkaline Phosphatase)-1.5 ± 8.4-1.9 ± 14.6-2.2 ± 6.3-2.5 ± 6.7-3.0 ± 8.2
Week 4: Change from baseline (Alkaline Phosphatase)-1.1 ± 6.1-5.2 ± 8.63.2 ± 13.1-3.8 ± 8.1-4.1 ± 8.8
Week 8: Change from baseline (Alkaline Phosphatase)-2.0 ± 8.5-5.0 ± 10.8-1.0 ± 6.2-5.1 ± 10.8-4.5 ± 12.0
Week 12: Change from baseline (Alkaline Phosphatase)-0.5 ± 8.2-3.2 ± 8.90.2 ± 11.5-4.4 ± 11.8-4.5 ± 8.1
Week 16: Change from baseline (Alkaline Phosphatase)-0.1 ± 8.5-0.6 ± 14.2-4.9 ± 10.4-0.1 ± 9.6-2.6 ± 8.0
Baseline (Aspartate Aminotransferase)24.7 ± 6.024.4 ± 6.524.4 ± 5.124.8 ± 8.024.9 ± 6.0
Week 2: Change from baseline (Aspartate Aminotransferase)0.9 ± 7.10.0 ± 4.00.1 ± 4.2-2.0 ± 7.6-2.3 ± 6.1
Week 4: Change from baseline (Aspartate Aminotransferase)1.5 ± 6.3-0.2 ± 3.84.6 ± 17.7-1.8 ± 6.7-0.3 ± 6.9
Week 8: Change from baseline (Aspartate Aminotransferase)-1.3 ± 5.0-0.5 ± 4.73.4 ± 24.2-1.8 ± 6.9-1.2 ± 5.2
Week 12: Change from baseline (Aspartate Aminotransferase)-1.1 ± 4.30.3 ± 3.50.9 ± 8.1-1.8 ± 4.7-2.0 ± 7.6
Week 16: Change from baseline (Aspartate Aminotransferase)0.7 ± 5.10.9 ± 7.5-2.4 ± 3.6-0.2 ± 8.5-2.2 ± 5.3
Baseline (Alanine Aminotransferase)27.0 ± 8.724.0 ± 7.623.9 ± 10.024.4 ± 10.025.9 ± 9.0
Week 2: Change from baseline (Alanine Aminotransferase)0.8 ± 10.6-0.1 ± 5.1-0.7 ± 5.6-2.1 ± 6.7-3.0 ± 7.6
Week 4: Change from baseline (Alanine Aminotransferase)3.5 ± 11.6-1.0 ± 5.516.4 ± 70.2-2.1 ± 5.3-1.1 ± 9.5
Week 8: Change from baseline (Alanine Aminotransferase)-0.7 ± 6.1-0.3 ± 5.20.6 ± 12.2-0.4 ± 9.2-0.7 ± 10.6
Week 12: Change from baseline (Alanine Aminotransferase)-0.5 ± 7.40.7 ± 6.04.3 ± 21.0-0.6 ± 6.8-1.2 ± 9.1
Week 16: Change from baseline (Alanine Aminotransferase)2.5 ± 13.12.0 ± 9.1-3.5 ± 6.93.1 ± 12.0-2.4 ± 6.7
Baseline (Gamma Glutamyl Transferase )24.6 ± 17.425.1 ± 15.019.3 ± 15.325.5 ± 23.225.9 ± 28.0
Week 2: Change from baseline (Gamma Glutamyl Transferase)-0.2 ± 11.30.0 ± 7.1-1.9 ± 6.7-2.7 ± 8.4-1.0 ± 7.6
Week 4: Change from baseline (Gamma Glutamyl Transferase)3.0 ± 14.8-0.6 ± 9.13.6 ± 14.7-3.5 ± 10.61.4 ± 14.6
Week 8: Change from baseline (Gamma Glutamyl Transferase)-1.5 ± 6.40.1 ± 9.20.6 ± 5.9-2.8 ± 13.63.3 ± 22.6
Week 12: Change from baseline (Gamma Glutamyl Transferase)-1.2 ± 10.71.5 ± 9.84.8 ± 13.2-3.0 ± 14.31.3 ± 16.2
Week 16: Change from baseline (Gamma Glutamyl Transferase)-0.7 ± 8.82.2 ± 10.11.8 ± 14.4-0.7 ± 10.1-0.2 ± 16.4
SecondaryChange From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Protein and Albumin

Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.

Time frame:
From baseline to Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · g/L
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Protein and Albumin
g/LPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline (Protein)67.4 ± 4.067.5 ± 4.366.5 ± 5.167.7 ± 4.367.0 ± 4.7
Week 2: Change from baseline (Protein)-1.7 ± 2.9-2.1 ± 4.6-0.4 ± 3.7-1.5 ± 2.9-2.1 ± 3.7
Week 4: Change from baseline (Protein)-1.8 ± 3.0-1.5 ± 4.10.2 ± 3.3-1.6 ± 2.7-1.5 ± 3.5
Week 8: Change from baseline (Protein)-1.5 ± 3.4-2.3 ± 4.2-1.7 ± 4.2-2.0 ± 3.8-2.4 ± 3.3
Week 12: Change from baseline (Protein)-1.5 ± 3.0-1.5 ± 3.9-0.7 ± 4.6-1.7 ± 3.4-1.8 ± 3.2
Week 16: Change from baseline (Protein)-1.0 ± 3.2-1.6 ± 4.1-1.9 ± 5.0-1.8 ± 3.7-1.7 ± 4.0
Baseline (Albumin)44.7 ± 2.144.9 ± 2.843.6 ± 2.445.2 ± 2.444.2 ± 3.0
Week 2: Change from baseline (Albumin)-1.3 ± 1.9-1.4 ± 2.6-0.1 ± 2.4-0.9 ± 1.8-1.3 ± 2.4
Week 4: Change from baseline (Albumin)-0.9 ± 2.1-1.0 ± 2.30.5 ± 2.2-0.8 ± 1.9-0.7 ± 2.6
Week 8: Change from baseline (Albumin)-0.8 ± 2.2-1.2 ± 2.7-0.9 ± 2.5-0.8 ± 2.6-1.3 ± 2.2
Week 12: Change from baseline (Albumin)-0.6 ± 1.9-0.7 ± 2.10.3 ± 2.6-0.6 ± 2.5-0.7 ± 2.2
Week 16: Change from baseline (Albumin)0.0 ± 2.0-0.4 ± 2.00.1 ± 3.1-0.6 ± 2.3-0.4 ± 2.8
SecondaryChange From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Hemoglobin A1C

Blood samples for clinical chemistry assessment were collected and sent to the central laboratory for analysis.

Time frame:
From baseline to Weeks 2, 4, 8, 12 and 16
Reported as:
Mean · mmol/mol
Change From Baseline at Weeks 2, 4, 8, 12 and 16 in Clinical Laboratory Parameters Biochemistry: Hemoglobin A1C
mmol/molPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline39.22 ± 8.0939.05 ± 5.8235.84 ± 3.3938.78 ± 5.6540.88 ± 10.97
Week 2: Change from baseline-0.42 ± 1.460.04 ± 1.180.19 ± 1.46-0.08 ± 1.35-0.21 ± 2.32
Week 4: Change from baseline-0.29 ± 1.910.00 ± 1.960.06 ± 1.47-0.02 ± 1.55-0.43 ± 4.24
Week 8: Change from baseline-0.40 ± 2.380.26 ± 2.160.62 ± 2.13-0.13 ± 1.72-0.28 ± 5.11
Week 12: Change from baseline0.07 ± 1.960.84 ± 3.011.57 ± 2.460.55 ± 2.30-0.94 ± 5.33
Week 16: Change from baseline-0.64 ± 2.410.69 ± 2.641.16 ± 2.13-0.04 ± 2.22-1.07 ± 5.65
SecondaryChange From Baseline at Weeks 12 and 16 in Clinical Laboratory Parameters Bone: Bone Specific Alkaline Phosphatase and Procollagen 1 N-Terminal Propeptide

Blood for assessment of bone turnover markers was collected and sent to the central laboratory for analysis.

Time frame:
From baseline to Weeks 12 and 16
Reported as:
Mean · ug/L
Change From Baseline at Weeks 12 and 16 in Clinical Laboratory Parameters Bone: Bone Specific Alkaline Phosphatase and Procollagen 1 N-Terminal Propeptide
ug/LPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline (Bone Specific Alkaline Phosphatase)12.17 ± 5.0813.01 ± 5.0913.94 ± 4.6713.37 ± 4.6913.36 ± 4.83
Week 12: Change from baseline (Bone Specific Alkaline Phosphatase)0.48 ± 2.220.34 ± 4.24-0.68 ± 3.36-0.43 ± 2.50-0.11 ± 2.73
Week 16: Change from baseline (Bone Specific Alkaline Phosphatase)0.86 ± 3.571.22 ± 7.58-1.18 ± 2.490.84 ± 3.550.48 ± 2.98
Baseline (Procollagen 1 N-Terminal Propeptide)58.1 ± 23.368.0 ± 24.767.6 ± 15.668.6 ± 29.359.5 ± 23.6
Week 12: Change from baseline (Procollagen 1 N-Terminal Propeptide)5.0 ± 14.50.5 ± 10.9-5.7 ± 15.9-2.1 ± 13.7-0.7 ± 10.9
Week 16: Change from baseline (Procollagen 1 N-Terminal Propeptide)3.6 ± 20.2-1.9 ± 9.7-0.9 ± 19.6-2.5 ± 15.40.0 ± 11.7
SecondaryChange From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: pH

Urine for urinalysis was collected and sent to the central laboratory for analysis. Urine pH was measured on a pH scale.

Time frame:
From baseline to Weeks 2, 4, 12 and 16
Reported as:
Mean · pH
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: pH
pHPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline (pH)6.00 ± 0.836.10 ± 0.896.09 ± 0.926.21 ± 0.756.08 ± 0.72
Week 2: Change from baseline (pH)0.10 ± 0.700.26 ± 0.90-0.15 ± 0.95-0.30 ± 0.83-0.20 ± 0.83
Week 4: Change from baseline (pH)-0.11 ± 0.850.18 ± 1.31-0.09 ± 0.80-0.25 ± 0.83-0.09 ± 0.89
Week 12: Change from baseline (pH)-0.05 ± 0.890.18 ± 1.06-0.19 ± 0.83-0.21 ± 0.78-0.06 ± 0.79
Week 16: Change from baseline (pH)0.05 ± 1.130.00 ± 1.12-0.03 ± 0.90-0.19 ± 0.840.07 ± 1.04
SecondaryChange From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Specific Gravity

Urine for urinalysis was collected and sent to the central laboratory for analysis.

Time frame:
From baseline to Weeks 2, 4, 12 and 16
Reported as:
Mean · Unitless
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Specific Gravity
UnitlessPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline (Specific Gravity)1.0167 ± 0.00631.0167 ± 0.00831.0166 ± 0.00631.0154 ± 0.00641.0171 ± 0.0084
Week 2: Change from baseline (Specific Gravity)-0.0002 ± 0.0066-0.0011 ± 0.00850.0001 ± 0.00600.0005 ± 0.0068-0.0006 ± 0.0060
Week 4: Change from baseline (Specific Gravity)-0.0008 ± 0.00780.0012 ± 0.0086-0.0026 ± 0.00630.0015 ± 0.00670.0003 ± 0.0079
Week 12: Change from baseline (Specific Gravity)0.0020 ± 0.00680.0015 ± 0.0102-0.0012 ± 0.00600.0002 ± 0.00680.0011 ± 0.0072
Week 16: Change from baseline (Specific Gravity)0.0009 ± 0.00880.0002 ± 0.0093-0.0011 ± 0.00590.0020 ± 0.0066-0.0006 ± 0.0066
SecondaryChange From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Glucose, Bilirubin, Ketones, Occult Blood, Protein, Urobilinogen and Nitrite

Urine for urinalysis was collected and sent to the central laboratory for analysis. Clinical relevance was judged by the investigator. Assessment was done using standard laboratory practice. For evaluation of the chemical properties of the urine sample test strips were used which have test pads of chemicals that change color when they come in contact with reagents. The degree of color change correlates with the amount of reagent present. Each color block represents a range of values. Range and direction of scores for reagents nitrite and urobilinogen: negative = normal; positive = abnormal. Range and direction of scores for all other reagents tested: negative = normal; trace, 1+, 2+, 3+ = abnormal, the higher the value, the higher the concentration of the reagent tested.

Time frame:
From baseline to Weeks 2, 4, 12 and 16
Reported as:
Number · Participants
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Glucose, Bilirubin, Ketones, Occult Blood, Protein, Urobilinogen and Nitrite
ParticipantsPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline (Glucose): Negative4630174948
Baseline (Glucose): Trace10001
Baseline (Glucose): 1+01000
Baseline (Glucose): 2+00000
Baseline (Glucose): 3+00002
Week 2 (Glucose): Negative4431175249
Week 2 (Glucose): Trace00000
Week 2 (Glucose): 1+00001
Week 2 (Glucose): 2+00000
Week 2 (Glucose): 3+00001
Week 4 (Glucose): Negative4530175146
Week 4 (Glucose): Trace01000
Week 4 (Glucose): 1+00000
Week 4 (Glucose): 2+00000
Week 4 (Glucose): 3+00002
Week 12 (Glucose): Negative4330164740
Week 12 (Glucose): Trace00011
Week 12 (Glucose): 1+00001
Week 12 (Glucose): 2+00000
Week 12 (Glucose): 3+00012
Week 16 (Glucose): Negative4029165043
Week 16 (Glucose): Trace01000
Week 16 (Glucose): 1+10000
Week 16 (Glucose): 2+00000
Week 16 (Glucose): 3+00011
Baseline (Bilirubin): Negative4731174951
Baseline (Bilirubin): 1+00000
Week 2 (Bilirubin): Negative4431175251
Week 2 (Bilirubin): 1+00000
Week 4 (Bilirubin): Negative4531175148
Week 4 (Bilirubin): 1+00000
Week 12 (Bilirubin): Negative4330164944
Week 12 (Bilirubin): 1+00000
Week 16 (Bilirubin): Negative4129165144
Week 16 (Bilirubin): 1+01000
Baseline (Ketones): Negative4631174850
Baseline (Ketones): Trace10011
Week 2 (Ketones): Negative4431175150
Week 2 (Ketones): Trace00011
Week 4 (Ketones): Negative4531175048
Week 4 (Ketones): Trace00010
Week 12 (Ketones): Negative4230164843
Week 12 (Ketones): Trace10011
Week 16 (Ketones): Negative4130165044
Week 16 (Ketones): Trace00010
Baseline (Occult Blood): Negative4628154247
Baseline (Occult Blood): Trace03134
Baseline (Occult Blood): 1+10030
Baseline (Occult Blood): 2+00010
Baseline (Occult Blood): 3+00100
Week 2 (Occult Blood): Negative4229174547
Week 2 (Occult Blood): Trace12013
Week 2 (Occult Blood): 1+10051
Week 2 (Occult Blood): 2+00010
Week 2 (Occult Blood): 3+00000
Week 4 (Occult Blood): Negative4328174247
Week 4 (Occult Blood): Trace21051
Week 4 (Occult Blood): 1+02030
Week 4 (Occult Blood): 2+00000
Week 4 (Occult Blood): 3+00010
Week 12 (Occult Blood): Negative4030134042
Week 12 (Occult Blood): Trace10152
Week 12 (Occult Blood): 1+20130
Week 12 (Occult Blood): 2+00110
Week 12 (Occult Blood): 3+00000
Week 16 (Occult Blood): Negative3827144539
Week 16 (Occult Blood): Trace23134
Week 16 (Occult Blood): 1+00031
Week 16 (Occult Blood): 2+10000
Week 16 (Occult Blood): 3+00100
Baseline (Protein): Negative4531164849
Baseline (Protein): Trace20111
Baseline (Protein): 1+00001
Baseline (Protein): 2+00000
Baseline (Protein): 3+00000
Week 2 (Protein): Negative4431175249
Week 2 (Protein): Trace00000
Week 2 (Protein): 1+00000
Week 2 (Protein): 2+00002
Week 2 (Protein): 3+00000
Week 4 (Protein): Negative4431174945
Week 4 (Protein): Trace00023
Week 4 (Protein): 1+10000
Week 4 (Protein): 2+00000
Week 4 (Protein): 3+00000
Week 12 (Protein): Negative4130144743
Week 12 (Protein): Trace10011
Week 12 (Protein): 1+10210
Week 12 (Protein): 2+00000
Week 12 (Protein): 3+00000
Week 16 (Protein): Negative3930155043
Week 16 (Protein): Trace10001
Week 16 (Protein): 1+00010
Week 16 (Protein): 2+00100
Week 16 (Protein): 3+10000
Baseline (Urobilinogen): Negative4731174951
Week 2 (Urobilinogen): Negative4431175251
Week 4 (Urobilinogen): Negative4531175148
Week 12 (Urobilinogen): Negative4330164944
Week 16 (Urobilinogen): Negative4130165144
Baseline (Nitrite): Negative4729174848
Baseline (Nitrite): Positive02013
Week 2 (Nitrite): Negative4429175147
Week 2 (Nitrite): Positive02014
Week 4 (Nitrite): Negative4529175047
Week 4 (Nitrite): Positive02011
Week 12 (Nitrite): Negative4229164942
Week 12 (Nitrite): Positive11002
Week 16 (Nitrite): Negative4130165142
Week 16 (Nitrite): Positive00002
SecondaryChange From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Erythrocytes and Leukocytes

Urine for urinalysis was collected and sent to the central laboratory for analysis. Results are reported according to the amount present in the microscope's field of view at high magnification (/HPF \[high-power field\]).

Time frame:
From baseline to Weeks 2, 4, 12 and 16
Reported as:
Mean · cells/HPF
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Erythrocytes and Leukocytes
cells/HPFPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline (Erythrocytes (/HPF))1.3 ± 1.50.8 ± 1.12.0 ± 2.61.5 ± 2.40.6 ± 0.7
Week 2: Change from baseline (Erythrocytes (/HPF))-0.6 ± 2.6-0.6 ± 0.5-1.0 ± 1.4-0.8 ± 4.00.9 ± 3.0
Week 4: Change from baseline (Erythrocytes (/HPF))-0.1 ± 1.60.5 ± 1.3-2.7 ± 3.1-0.5 ± 3.10.3 ± 1.1
Week 12: Change from baseline (Erythrocytes (/HPF))-0.4 ± 2.2-0.4 ± 0.80.4 ± 0.51.4 ± 3.70.2 ± 1.5
Week 16: Change from baseline (Erythrocytes (/HPF))-0.3 ± 2.1-0.7 ± 1.2-1.5 ± 2.40.3 ± 2.10.1 ± 0.3
Baseline (Leukocytes (/HPF))9.5 ± 16.22.6 ± 4.31.6 ± 1.75.3 ± 11.93.0 ± 5.8
Week 2: Change from baseline (Leukocytes (/HPF))-6.7 ± 15.90.0 ± 3.60.5 ± 2.1-1.0 ± 2.7-0.4 ± 6.4
Week 4: Change from baseline (Leukocytes (/HPF))-6.0 ± 20.91.0 ± 1.06.3 ± 11.80.3 ± 4.10.8 ± 5.8
Week 12: Change from baseline (Leukocytes (/HPF))6.4 ± 47.93.5 ± 6.70.6 ± 3.00.6 ± 2.3-1.5 ± 5.1
Week 16: Change from baseline (Leukocytes (/HPF))-7.6 ± 21.93.0 ± 4.43.0 ± 4.20.6 ± 1.313.3 ± 33.4
SecondaryChange From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Hyaline Casts

Urine for urinalysis was collected and sent to the central laboratory for analysis. Results are reported according to the amount present in the microscope's field of view at low magnification (/LPF \[low-power field\]).

Time frame:
From baseline to Weeks 2, 4, 12 and 16
Reported as:
Mean · cells/LPF
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Hyaline Casts
cells/LPFPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline (Hyaline Casts (/LPF)1.9 ± 2.00.8 ± 1.60.1 ± 0.40.8 ± 1.41.7 ± 6.2
Week 2: Change from baseline (Hyaline Casts (/LPF))-1.1 ± 2.7-0.6 ± 1.50.0 ± 0.0-0.1 ± 0.60.1 ± 1.5
Week 4: Change from baseline (Hyaline Casts (/LPF))-0.2 ± 3.6-0.5 ± 1.05.3 ± 6.80.3 ± 1.8-0.4 ± 1.7
Week 12: Change from baseline (Hyaline Casts (/LPF))-0.3 ± 2.8-0.1 ± 1.52.2 ± 4.4-0.3 ± 0.8-2.8 ± 9.0
Week 16: Change from baseline (Hyaline Casts (/LPF))-1.2 ± 2.90.7 ± 1.20.5 ± 1.00.1 ± 0.8-0.2 ± 0.8
SecondaryChange From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Bacteria, Yeast Cells, Granular Casts, RBC Casts, Waxy Casts, WBC Casts, Calcium Oxalate Crystals, Triple Phosphate Crystals and Uric Acid Crystals

Urine for urinalysis was collected and sent to the central laboratory for analysis. The evaluation of components in the urine samples such as bacteria, yeast, red blood cells (RBC), white blood cells (WBC), casts and crystals was performed by microscopy. Results are reported according to the amount present in the microscope's field of view at low magnification (/LPF \[low-power field\]) and high magnification (/HPF \[high-power field\]). Range and direction of scores microscopic identification of urine components: * Bacteria: none seen, 1+, 2+, 3+,4+, TNTC (too numerous to count). * Other urine components: none seen=normal; few, moderate, many, TNTC = abnormal. The higher the value, the higher the concentration of the component evaluated.

Time frame:
From baseline to Weeks 2, 4, 12 and 16
Reported as:
Number · Participants
Change From Baseline at Weeks 2, 4, 12 and 16 in Clinical Laboratory Parameters Urinalysis: Bacteria, Yeast Cells, Granular Casts, RBC Casts, Waxy Casts, WBC Casts, Calcium Oxalate Crystals, Triple Phosphate Crystals and Uric Acid Crystals
ParticipantsPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
Baseline (Bacteria(/HPF)): None seen44297
Baseline (Bacteria(/HPF)): 1+43165
Baseline (Bacteria(/HPF)): 2+01112
Baseline (Bacteria(/HPF)): 3+01002
Baseline (Bacteria(/HPF)): 4+00111
Baseline (Bacteria(/HPF)): TNTC12002
Week 2 (Bacteria(/HPF)): None seen33156
Week 2 (Bacteria(/HPF)): 1+12144
Week 2 (Bacteria(/HPF)): 2+12106
Week 2 (Bacteria(/HPF)): 3+01011
Week 2 (Bacteria(/HPF)): 4+20000
Week 2 (Bacteria(/HPF)): TNTC11011
Week 4 (Bacteria(/HPF)): None seen73192
Week 4 (Bacteria(/HPF)): 1+00113
Week 4 (Bacteria(/HPF)): 2+20143
Week 4 (Bacteria(/HPF)): 3+00001
Week 4 (Bacteria(/HPF)): 4+00002
Week 4 (Bacteria(/HPF)): TNTC23012
Week 12 (Bacteria(/HPF)): None seen133113
Week 12 (Bacteria(/HPF)): 1+72333
Week 12 (Bacteria(/HPF)): 2+10235
Week 12 (Bacteria(/HPF)): 3+10010
Week 12 (Bacteria(/HPF)): 4+01000
Week 12 (Bacteria(/HPF)): TNTC22001
Week 16 (Bacteria(/HPF)): None seen23264
Week 16 (Bacteria(/HPF)): 1+50033
Week 16 (Bacteria(/HPF)): 2+42111
Week 16 (Bacteria(/HPF)): 3+10012
Week 16 (Bacteria(/HPF)): 4+11203
Week 16 (Bacteria(/HPF)): TNTC00011
Baseline (Yeast Cells(/HPF)): None seen91151719
Baseline (Yeast Cells(/HPF)): Few00000
Week 2 (Yeast Cells(/HPF)): None seen8931117
Week 2 (Yeast Cells(/HPF)): Few00001
Week 4 (Yeast Cells(/HPF)): None seen11631513
Week 4 (Yeast Cells(/HPF)): Few00000
Week 12 (Yeast Cells(/HPF)): None seen12881812
Week 12 (Yeast Cells(/HPF)): Few00000
Week 16 (Yeast Cells(/HPF)): None seen13651214
Week 16 (Yeast Cells(/HPF)): Few00000
Baseline (Granular Casts(/LPF)): None seen91151719
Week 2: (Granular Casts(/LPF)): None seen8931118
Week 4: (Granular Casts(/LPF)): None seen11631513
Week 12: (Granular Casts(/LPF)): None seen12881812
Week 16: (Granular Casts(/LPF)): None seen13651214
Baseline (RBC Casts(/LPF)): None seen91151719
Week 2 (RBC Casts(/LPF)): None seen8931118
Week 4 (RBC Casts(/LPF)): None seen11631513
Week 12 (RBC Casts(/LPF)): None seen12881812
Week 16 (RBC Casts(/LPF)): None seen13651214
Baseline (Waxy Casts(/LPF)): None seen91151719
Week 2 (Waxy Casts(/LPF)): None seen8931118
Week 4 (Waxy Casts(/LPF)): None seen11631513
Week 12 (Waxy Casts(/LPF)): None seen12881812
Week 16 (Waxy Casts(/LPF)): None seen13651214
Baseline (WBC Casts(/LPF)): None seen91151719
Week 2 (WBC Casts(/LPF)): None seen8931118
Week 4 (WBC Casts(/LPF)): None seen11631513
Week 12 (WBC Casts(/LPF)): None seen12881812
Week 16 (WBC Casts(/LPF)): None seen13651214
Baseline (Calcium Oxalate Crystals(/HPF)): None seen81151316
Baseline (Calcium Oxalate Crystals(/HPF)): Few10022
Baseline (Calcium Oxalate Crystals(/HPF)): Moderate00001
Baseline (Calcium Oxalate Crystals(/HPF)): Many00020
Baseline (Calcium Oxalate Crystals(/HPF)): TNTC00000
Week 2 (Calcium Oxalate Crystals(/HPF)): None seen683917
Week 2 (Calcium Oxalate Crystals(/HPF)): Few20010
Week 2 (Calcium Oxalate Crystals(/HPF)): Moderate00001
Week 2 (Calcium Oxalate Crystals(/HPF)): Many01010
Week 2 (Calcium Oxalate Crystals(/HPF)): TNTC00000
Week 4 (Calcium Oxalate Crystals(/HPF)): None seen9531210
Week 4 (Calcium Oxalate Crystals(/HPF)): Few00011
Week 4 (Calcium Oxalate Crystals(/HPF)): Moderate11010
Week 4 (Calcium Oxalate Crystals(/HPF)): Many10011
Week 4 (Calcium Oxalate Crystals(/HPF)): TNTC00001
Week 12 (Calcium Oxalate Crystals(/HPF)): None seen11781611
Week 12 (Calcium Oxalate Crystals(/HPF)): Few10001
Week 12 (Calcium Oxalate Crystals(/HPF)): Moderate01010
Week 12 (Calcium Oxalate Crystals(/HPF)): Many00010
Week 12 (Calcium Oxalate Crystals(/HPF)): TNTC00000
Week 16 (Calcium Oxalate Crystals(/HPF)): None seen10451114
Week 16 (Calcium Oxalate Crystals(/HPF)): Few22000
Week 16 (Calcium Oxalate Crystals(/HPF)): Moderate10000
Week 16 (Calcium Oxalate Crystals(/HPF)): Many00010
Week 16 (Calcium Oxalate Crystals(/HPF)): TNTC00000
Baseline (Triple Phosphate Crystals(/HPF)): None seen91151719
Week 2 (Triple Phosphate Crystals(/HPF)): None seen8931118
Week 4 (Triple Phosphate Crystals(/HPF)): None seen11631513
Week 12 (Triple Phosphate Crystals(/HPF)): None seen12881812
Week 16 (Triple Phosphate Crystals(/HPF)): None seen13651214
Baseline (Uric Acid Crystals(/HPF)): None seen91151619
Baseline (Uric Acid Crystals(/HPF)): Few00010
Baseline (Uric Acid Crystals(/HPF)): Moderate00000
Week 2 (Uric Acid Crystals(/HPF)): None seen8931118
Week 2 (Uric Acid Crystals(/HPF)): Few00000
Week 2 (Uric Acid Crystals(/HPF)): Moderate00000
Week 4 (Uric Acid Crystals(/HPF)): None seen11631412
Week 4 (Uric Acid Crystals(/HPF)): Few00001
Week 4 (Uric Acid Crystals(/HPF)): Moderate00010
Week 12 (Uric Acid Crystals(/HPF)): None seen11881812
Week 12 (Uric Acid Crystals(/HPF)): Few10000
Week 12 (Uric Acid Crystals(/HPF)): Moderate00000
Week 16 (Uric Acid Crystals(/HPF)): None seen13641114
Week 16 (Uric Acid Crystals(/HPF)): Few00110
Week 16 (Uric Acid Crystals(/HPF)): Moderate00000

Adverse events

Collected over On or after first dosing with randomised study treatment up to Week 16. Adverse event reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to 1 year.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/47 (0%)2/47 (4.3%)18/47 (38.3%)
40 mg Elinzanetant (BAY3427080)0/31 (0%)0/31 (0%)13/31 (41.9%)
80 mg Elinzanetant (BAY3427080)0/17 (0%)1/17 (5.9%)14/17 (82.4%)
120 mg Elinzanetant (BAY3427080)0/52 (0%)1/52 (1.9%)23/52 (44.2%)
160 mg Elinzanetant (BAY3427080)0/52 (0%)1/52 (1.9%)23/52 (44.2%)
Most frequent serious events
Most frequent serious events
EventPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
NephrolithiasisRenal and urinary disorders0/470/311/170/520/52
SepsisInfections and infestations1/470/310/170/520/52
Infective exacerbation of chronic obstructive airways diseaseInfections and infestations1/470/310/170/520/52
Tooth abscessInfections and infestations0/470/310/170/521/52
MigraineNervous system disorders0/470/310/171/520/52
Most frequent other events
Showing 10 of 29
Most frequent other events
EventPlacebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)
HeadacheNervous system disorders6/473/312/176/524/52
DiarrhoeaGastrointestinal disorders3/472/312/173/523/52
NauseaGastrointestinal disorders2/472/312/171/522/52
Herpes zosterInfections and infestations0/470/312/170/520/52
SomnolenceNervous system disorders1/473/311/172/526/52
FatigueGeneral disorders0/473/311/171/524/52
NasopharyngitisInfections and infestations4/471/310/173/520/52
Urinary tract infectionInfections and infestations1/472/310/172/522/52
Arthropod biteInjury, poisoning and procedural complications1/472/310/171/521/52
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/472/310/170/522/52

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)Total
Mean55.6 ± 4.155.4 ± 4.055.9 ± 4.254.8 ± 4.455.0 ± 3.855.1 ± 4.1
Sex: Female, Male
Sex: Female, Male(Participants)Placebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)Total
Female4731175252199
Male000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)Total
Hispanic or Latino2212613
Not Hispanic or Latino4529165046186
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo40 mg Elinzanetant (BAY3427080)80 mg Elinzanetant (BAY3427080)120 mg Elinzanetant (BAY3427080)160 mg Elinzanetant (BAY3427080)Total
American Indian or Alaska Native000000
Asian200114
Native Hawaiian or Other Pacific Islander000000
Black or African American653131138
White3824133740152
More than one race000000
Unknown or Not Reported121105
08

Study locations

25 sites
  • Study Site 12
    Mesa, Arizona 85209, United States
  • Study Site 19
    San Diego, California 92108, United States
  • Study Site 13
    Aventura, Florida 33180, United States
  • Study Site 15
    Lake Worth, Florida 33461, United States
  • Study Site 18
    Atlanta, Georgia 30328, United States
  • Study Site 16
    New Orleans, Louisiana 70125, United States
  • Study Site 10
    Boston, Massachusetts 02114, United States
  • Study Site 11
    Boston, Massachusetts 02115, United States
  • Study Site 17
    Las Vegas, Nevada 89128, United States
  • Study Site 14
    Houston, Texas 77054, United States
  • Study Site 50
    Red Deer, Alberta, Canada
  • Study Site 51
    Mission, British Columbia, Canada
  • Study Site 54
    Guelph, Ontario, Canada
  • Study Site 52
    Scarborough, Ontario, Canada
  • Study Site 53
    Toronto, Ontario, Canada
  • Study Site 37
    Blackpool, United Kingdom
  • Study Site 34
    Cannock, United Kingdom
  • Study Site 31
    Glasgow, United Kingdom
  • Study Site 39
    Leeds, United Kingdom
  • Study Site 38
    Liverpool, United Kingdom
  • Study Site 30
    London, United Kingdom
  • Study Site 36
    Manchester, United Kingdom
  • Study Site 33
    Poole, United Kingdom
  • Study Site 32
    Southport, United Kingdom
  • Study Site 35
    Stockton-on-Tees, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Nov 2019, 12 months.

Results were first posted in Mar 2023, 3 years 3 months after primary completion. A results delay was requested in Nov 2020.

Of 24 phase 2 interventional studies under Hot Flashes, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2018
First posted
Jul 24, 2018
StartActual
Nov 20, 2018
Primary completionActual
Nov 21, 2019
CompletionActual
Nov 21, 2019
Results delay requested
Nov 16, 2020
Results first posted
Mar 10, 2023
Last update
Mar 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03596762
Lead sponsor
Bayer
Collaborators
Nerre Therapeutics Ltd.
Responsible party
Sponsor
First posted
Jul 24, 2018
Start date
Nov 20, 2018
Primary completion
Nov 21, 2019
Completion
Nov 21, 2019
Results posted
Mar 10, 2023
Last update
Mar 10, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elinzanetant

Start the discussion